

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3887843

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	FORECLOSURE DOCUMENTS	
SEQUENCE:	1	
CONVEYING PARTY DATA		
Name		Execution Date
VINDRAUGA HOLDINGS, LLC		04/05/2016
RECEIVING PARTY DATA		
Name:	VINDRAUGA HOLDINGS, LLC	
Street Address:	1565 HOTEL CIRCLE SOUTH, SUITE 310	
City:	SAN DIEGO	
State/Country:	CALIFORNIA	
Postal Code:	92108	
PROPERTY NUMBERS Total: 40		
Property Type	Number	
Application Number:	60748824	
Application Number:	12305950	
Application Number:	60784322	
Application Number:	60796585	
Application Number:	11850550	
Application Number:	13446382	
Application Number:	13903346	
Application Number:	60824471	
Application Number:	60910217	
Application Number:	61033726	
Application Number:	12921349	
Application Number:	61033721	
Application Number:	61033731	
Application Number:	61036013	
Application Number:	12922365	
Application Number:	61105641	
Application Number:	12579733	
Application Number:	61115710	
Application Number:	12620831	

PATENT

Property Type	Number
Application Number:	13892714
Application Number:	61298443
Application Number:	13014413
Application Number:	61165662
Application Number:	12753022
Application Number:	61166986
Application Number:	12754770
Application Number:	61798910
Application Number:	14211560
Application Number:	61420141
Application Number:	13312553
Application Number:	14154989
Application Number:	62020033
Application Number:	14299303
PCT Number:	US2009060895
PCT Number:	US2009064967
PCT Number:	US2011022573
PCT Number:	US2010029720
PCT Number:	US2010030104
PCT Number:	US2014027774
PCT Number:	US2011063522

CORRESPONDENCE DATA

Fax Number: (626)395-0694

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6263957801

Email: rcallery@adrianoassociates.com

Correspondent Name: SARAH B. ADRIANO

Address Line 1: 690 EAST GREEN STREET, SUITE 300

Address Line 4: PASADENA, CALIFORNIA 91101

ATTORNEY DOCKET NUMBER:	30450.1USL1
NAME OF SUBMITTER:	SARAH B. ADRIANO
SIGNATURE:	/Sarah B. Adriano/
DATE SIGNED:	05/24/2016

Total Attachments: 83

source=16 may 24 Kirby Affidavit With Exhibits#page1.tif

source=16 may 24 Kirby Affidavit With Exhibits#page2.tif

source=16 may 24 Kirby Affidavit With Exhibits#page3.tif

source=16 may 24 Kirby Affidavit With Exhibits#page4.tif

[illegible]

source=16 may 24 Kirby Affidavit With Exhibits#page53.tif
source=16 may 24 Kirby Affidavit With Exhibits#page54.tif
source=16 may 24 Kirby Affidavit With Exhibits#page55.tif
source=16 may 24 Kirby Affidavit With Exhibits#page56.tif
source=16 may 24 Kirby Affidavit With Exhibits#page57.tif
source=16 may 24 Kirby Affidavit With Exhibits#page58.tif
source=16 may 24 Kirby Affidavit With Exhibits#page59.tif
source=16 may 24 Kirby Affidavit With Exhibits#page60.tif
source=16 may 24 Kirby Affidavit With Exhibits#page61.tif
source=16 may 24 Kirby Affidavit With Exhibits#page62.tif
source=16 may 24 Kirby Affidavit With Exhibits#page63.tif
source=16 may 24 Kirby Affidavit With Exhibits#page64.tif
source=16 may 24 Kirby Affidavit With Exhibits#page65.tif
source=16 may 24 Kirby Affidavit With Exhibits#page66.tif
source=16 may 24 Kirby Affidavit With Exhibits#page67.tif
source=16 may 24 Kirby Affidavit With Exhibits#page68.tif
source=16 may 24 Kirby Affidavit With Exhibits#page69.tif
source=16 may 24 Kirby Affidavit With Exhibits#page70.tif
source=16 may 24 Kirby Affidavit With Exhibits#page71.tif
source=16 may 24 Kirby Affidavit With Exhibits#page72.tif
source=16 may 24 Kirby Affidavit With Exhibits#page73.tif
source=16 may 24 Kirby Affidavit With Exhibits#page74.tif
source=16 may 24 Kirby Affidavit With Exhibits#page75.tif
source=16 may 24 Kirby Affidavit With Exhibits#page76.tif
source=16 may 24 Kirby Affidavit With Exhibits#page77.tif
source=16 may 24 Kirby Affidavit With Exhibits#page78.tif
source=16 may 24 Kirby Affidavit With Exhibits#page79.tif
source=16 may 24 Kirby Affidavit With Exhibits#page80.tif
source=16 may 24 Kirby Affidavit With Exhibits#page81.tif
source=16 may 24 Kirby Affidavit With Exhibits#page82.tif
source=16 may 24 Kirby Affidavit With Exhibits#page83.tif

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: The Patent Applications, Patents, and Trademarks identified in the Security Agreement referred to herein

AFFIDAVIT OF DEAN T. KIRBY, JR.

I, Dean T. Kirby, Jr., declare:

1. I am an attorney duly admitted to practice in the State of California. I am member of the law firm of Kirby & McGuinn, A P.C., 707 Broadway, Suite 1750, San Diego, CA 92101, attorneys for Vindrauga Corporation and for Vindrauga Holdings, LLC. Kirby & McGuinn represented both parties in relation to the foreclosure proceedings referred to below, and is the legal representative of those parties for this purpose. I have personal knowledge of the facts stated herein and could and would competently testify thereto if called as a witness.
2. A default has occurred with respect to the indebtedness secured by that certain Security Agreement dated as of November 7, 2013 which was recorded with the Patent Office under Reel 031601 and Frame numbers: 0321-0342 (for patents and patent applications) (**Exhibit 1**) and Trademark Office under Reel 005150 and Frame numbers: 0861-0882 (for trademarks) (**Exhibit 2**). The security interest created thereunder was perfected by the filing of a UCC-1 Financing Statement with the California Secretary of State on November 8, 2013 as Document No. 2013 4419884 (**Exhibit 3**), as amended by a UCC-2 Amendment filed April 23, 2015 as Document No. 2015 1744746 (**Exhibit 4**).
3. Prior to any disposition of collateral under the Security Agreement, the secured indebtedness was assigned by Vindrauga Corporation to Vindrauga Holdings, LLC, as evidenced by that certain Assignment dated April 4, 2016 (**Exhibit 5**) and

perfected by the filing of a UCC-2 Financing Statement Amendment filed with the California Secretary of State on April 4, 2016 as Document No. 2016 1991577 (**Exhibit 6**).

4. By reason of the default, a disposition of the intellectual property collateral described in the recorded Security Agreement, including without implied limitation the specific items listed in the collateral description attached to the Security Agreement (the "Intellectual Property Collateral") has taken place. A Notification of Intended Disposition of Collateral (**Exhibit 7**) was duly served, and at public auction held on April 5, 2016, the collateral was sold to the Secured Party, Vindrauga Holdings, LLC, by credit bid. To evidence the transfer of title to the collateral which occurred at the foreclosure sale, a Secured Party Bill of Sale (**Exhibit 8**) was executed. Also attached hereto is an Amended and Restated Secured Party Bill of Sale including an amended Exhibit "A" which more particularly describes certain items of the Collateral which were included in the general description attached to the original Secured Party Bill of Sale.
5. The Intellectual Property Collateral has thus been legally foreclosed upon under applicable California state law resulting in a complete transfer of ownership interest to the Secured Party, Vindrauga Holdings, LLC.
6. As evidenced by the Bill of Sale, and by the Amended and Restated Bill of Sale, Vindrauga Holdings, LLC is the owner of the Intellectual Property Collateral identified therein.

I declare under penalty of perjury under the laws of the United States that the foregoing is true and correct and that this Declaration was executed on May 23, 2016 at San Diego, California.



DEAN T. KIRBY, JR.

Exhibit 1

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1

Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY AGREEMENT
CONVEYING PARTY DATA	
Name	Execution Date
RIDGE DIAGNOSTICS, INC.	11/07/2013
RECEIVING PARTY DATA	
Name:	VINDRAUGA CORPORATION
Street Address:	1565 HOTEL CIRCLE SOUTH, SUITE 310
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92108
PROPERTY NUMBERS Total: 29	
Property Type	Number
Patent Number:	8158374
Patent Number:	8450077
Patent Number:	8440418
Application Number:	60748824
Application Number:	12305950
Application Number:	60784322
Application Number:	60796585
Application Number:	60910217
Application Number:	61033726
Application Number:	12921349
Application Number:	61033721
Application Number:	61033731
Application Number:	61036013
Application Number:	12922365
Application Number:	61105641
Application Number:	12579733

PATENT**REEL: 038831 FRAME: 0156**

Application Number:	61115710
Application Number:	13892714
Application Number:	61298443
Application Number:	13014413
Application Number:	61165662
Application Number:	12753022
Application Number:	61166986
Application Number:	12754770
Application Number:	61798910
Application Number:	61420141
Application Number:	13312553
Application Number:	13903346
Application Number:	60824471

CORRESPONDENCE DATA

Fax Number: (619)702-6858
Phone: (619) 685-3067
Email: hotaling@scmv.com
Correspondence will be sent via US Mail when the email attempt is unsuccessful.
Correspondent Name: ANDREW D. BROOKS
Address Line 1: 750 B STREET, SUITE 2100
Address Line 2: SELTZER CAPLAN MCMAHON VITEK
Address Line 4: SAN DIEGO, CALIFORNIA 92101

NAME OF SUBMITTER:	ANDREW D. BROOKS
---------------------------	------------------

Signature:	/Andrew D. Brooks/
-------------------	--------------------

Date:	11/08/2013
--------------	------------

Total Attachments: 20

source=IP Security Agreement Ridge wSchedule A#page1.tif
 source=IP Security Agreement Ridge wSchedule A#page2.tif
 source=IP Security Agreement Ridge wSchedule A#page3.tif
 source=IP Security Agreement Ridge wSchedule A#page4.tif
 source=IP Security Agreement Ridge wSchedule A#page5.tif
 source=IP Security Agreement Ridge wSchedule A#page6.tif
 source=IP Security Agreement Ridge wSchedule A#page7.tif
 source=IP Security Agreement Ridge wSchedule A#page8.tif
 source=IP Security Agreement Ridge wSchedule A#page9.tif
 source=IP Security Agreement Ridge wSchedule A#page10.tif
 source=IP Security Agreement Ridge wSchedule A#page11.tif
 source=IP Security Agreement Ridge wSchedule A#page12.tif
 source=IP Security Agreement Ridge wSchedule A#page13.tif
 source=IP Security Agreement Ridge wSchedule A#page14.tif
 source=IP Security Agreement Ridge wSchedule A#page15.tif
 source=IP Security Agreement Ridge wSchedule A#page16.tif
 source=IP Security Agreement Ridge wSchedule A#page17.tif
 source=IP Security Agreement Ridge wSchedule A#page18.tif

PATENT**REEL: 038831 FRAME: 0157**

source=IP Security Agreement Ridge wSchedule A#page19.tif
source=IP Security Agreement Ridge wSchedule A#page20.tif

RECEIPT INFORMATION

EPAS ID: PAT2608459
Receipt Date: 11/08/2013
Fee Amount: \$1160

PATENT**REEL: 038831 FRAME: 0158**

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT ("Agreement") is made as of November 7, 2013 by RIDGE DIAGNOSTICS, INC., a Delaware corporation ("Pledgor"), in favor of VINDRAUGA CORPORATION, a California corporation ("Lender"), with reference to the facts set forth below:

A. Pledgor has obtained a loan ("Loan") from VINDRAUGA CORPORATION, a California corporation ("Lender"), and in connection therewith has executed and delivered a Promissory Note dated of even date herewith (the "Note") in favor of Lender. Except as otherwise provided in this Agreement, terms with initial capital letters herein shall have the same meanings as set forth in the Note and that certain Loan Agreement, dated of even date herewith (the "Loan Agreement").

B. As a condition to making the Loan, Lender requires that Pledgor grant a security interest in and to certain property to Lender for purposes of securing all of the obligations to be performed by Pledgor pursuant to the Loan Agreement. Pledgor hereby acknowledges and agrees that it will derive personal benefit by Lender making the loan to Pledgor pursuant to the Loan Documents (defined below).

C. To induce Lender to make the Loan, Pledgor is willing to grant a security interest in and to such property to Lender on the provisions and conditions hereinafter set forth.

NOW, THEREFORE to induce Lender to make the Loan and in consideration for the making of the Loan, Pledgor agrees as set forth below:

1. Definitions: Interpretation.

(a) Defined Terms. As used in this Agreement, the following terms shall have the following meanings:

"Business" shall mean the current business operations of Pledgor and all future business operations of Pledgor.

"Collateral" has the meaning set forth in Section 2.

"Copyright Collateral" has the meaning set forth in Section 2.

"Copyrights" has the meaning set forth in Section 2.

"Event of Default" has the meaning ascribed thereto in Section 7.

"Existing Interest Holders" means any of the Persons holding the Existing Interests.

"Existing Interests" means any interests in the Collateral or portions thereof existing on the date hereof in favor of any of the Persons as listed on Schedule "B" pursuant to the agreements referred to therein.

"Lender" shall have the meaning ascribed to such term in the introductory paragraph of this Agreement.

"Lien" means any pledge, security interest, assignment, charge or encumbrance, lien (statutory or other), or other preferential arrangement (including any agreement to give any security interest).

"Loan Agreement" shall have the meaning ascribed to such term in the introductory paragraph of this Agreement and shall include all modifications, amendments, renewals, replacements and extensions thereof.

"Loan Documents" shall mean the Loan Agreement and all other documents executed by Pledgor or any other party in connection with evidencing or securing the Loan.

"Material Adverse Effect" means a circumstance or event or any set of circumstances or events which has or could reasonably be expected to have any material adverse effect upon: (a) the condition, operations, assets, business or prospects of Pledgor; (b) Pledgor's ability to pay and perform the Obligations; (c) the value or priority of Lender's security interest in any Collateral; and/or (d) the practical realization of the benefits of Lender's rights and remedies under this Agreement and the other Loan Documents.

"Obligations" shall have the meaning ascribed to such term in Section 3 of this Agreement.

"Patent Collateral" has the meaning set forth in Section 2.

"Patents" has the meaning set forth in Section 2.

"Person" means an individual, corporation, partnership, limited liability company, joint venture, trust, unincorporated organization or any other entity.

"Pledgor Documents" means this Agreement together with any collateral assignments of licenses made by Pledgor in favor of Lender, any security agreements for licenses made by Pledgor in favor of Lender, and all other similar documents relating to licenses executed by Pledgor in connection with the Loan Documents.

"Pledgor" shall have the meaning ascribed to such term in the introductory paragraph of this Agreement.

"Proceeds" means whatever is receivable or received from or upon the sale, lease, license, sublicense, franchise, subfranchise, collection, use, exchange or other disposition, whether voluntary or involuntary, of any Collateral, including "proceeds" as defined at UCC Section 9-102 (whether in the form of goods, money, instruments, chattel paper,

documents, accounts, deposit accounts, investment property, insurance, general intangibles, rights to proceeds of written letters of credit or otherwise), all insurance proceeds and all proceeds of proceeds. Proceeds shall also include: (i) any and all accounts, chattel paper, instruments, license fees, franchise fees, management fees, distributorship fees, royalties, required or permissible product purchase payments, general intangibles, cash and other proceeds, payable to or for the account of Pledgor, from time to time in respect of any of the Collateral and/or Pledgor's Business; (ii) any and all proceeds of any insurance, indemnity, warranty or guaranty payable to or for the account of Pledgor from time to time with respect to any of the Collateral; (iii) any and all claims and payments (in any form whatsoever) made or due and payable to Pledgor from time to time in connection with any requisition, confiscation, condemnation, seizure or forfeiture of all or any part of the Collateral by any Person acting under color of governmental authority; and (iv) any and all other amounts from time to time paid or payable under or in connection with any of the Collateral or for or on account of any damage or injury to or conversion of any Collateral by any Person.

"PTO" means the United States Patent and Trademark Office and any successor thereto.

"Trade Secret Collateral" has the meaning set forth in Section 2.

"Trade Secrets" has the meaning set forth in Section 2.

"Trademark Collateral" has the meaning set forth in Section 2,

"Trademarks" has the meaning set forth in Section 2.

"UCC" means the Uniform Commercial Code as in effect from time to time in the State of California.

"United States" and "U.S." each mean the United States of America.

(b) Terms Defined in UCC. Where applicable and except as otherwise defined herein, terms used in this Agreement shall have the meanings assigned to them in the UCC.

(c) Interpretation. In this Agreement, except to the extent the context otherwise requires: (i) any reference to a Section or a Schedule is a reference to a section hereof, or a schedule hereto, respectively, and to a subsection or a clause is, unless otherwise stated, a reference to a subsection or a clause of the Section or subsection in which the reference appears; (ii) the words "hereof," "herein," "hereto," "hereunder" and the like mean and refer to this Agreement as a whole and not merely to the specific Section, subsection, paragraph or clause in which the respective word appears; (iii) the meaning of defined terms shall be equally applicable to both the singular and plural forms of the terms defined; (iv) the words "including," "includes" and "include" shall be deemed to be followed by the words "without limitation"; (v) references to agreements and other contractual instruments shall be deemed to include all subsequent amendments and other modifications thereto; (vi) references to statutes or regulations are to be construed as including all statutory and regulatory provisions consolidating, amending or

replacing the statute or regulation referred to; and (vii) any captions and headings are for convenience of reference only and shall not affect the construction of this Agreement.

2. Security Interest. To secure the Obligations (as defined in Section 3 below), Pledgor does hereby irrevocably pledge, assign and grant to Lender a security interest in all of Pledgor's worldwide right, title and interest in and to all of the following property, now adopted, used, registered, unregistered, owned or hereafter acquired or created (collectively, the "Collateral"):

(a) Trademark Collateral. (i) All common law, state, federal and internationally registered trademarks, service marks, trade names, corporate names, company names, business names, fictitious business names, product names, slogans, trade styles, trade dress, color marks and designs, logos, domain names, other source or business identifiers, designs and general intangibles of like nature, now existing or hereafter adopted or acquired in any way relating to the Business or otherwise, together with and including all licenses therefor held by Pledgor, and all registrations and recordings thereof, and all applications filed or to be filed in connection therewith, and all extensions and renewals thereof, including, without limitation any of the foregoing identified on Schedule "A" hereto (as the same may be amended, modified or supplemented from time to time), together with the goodwill of the Business symbolized by or associated with all of the foregoing (collectively, the "Trademarks"); (ii) all modifications, variations, derivative marks and names based upon the Trademarks used in Pledgor's Business now or in the future, and the goodwill of the Business associated with such names and marks or other Trademarks; (iii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the Trademarks, including license fees and royalties under license and other agreements; (iv) all claims, causes of action, damages and recoveries for past, present and future infringements or unauthorized use of any of the Trademarks and all rights arising therefrom and pertaining thereto; (v) all rights corresponding to the Trademarks throughout the world; (vi) all general intangibles (as defined in the UCC) and all intangible intellectual property or other similar property of Pledgor of any kind or nature, whether now owned or hereafter acquired or used, associated with or arising out of any of the Trademarks (including without limitation all license, distributorship and/or franchise agreements and rights under any Existing Interests) not otherwise described herein and all of the goodwill of Pledgor's Business symbolized by the Trademarks or associated therewith; (vii) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (viii) all Proceeds and products of any and all of the foregoing (all of the foregoing, collectively, the "Trademark Collateral").

(b) Trade Secret Collateral. (i) All trade secrets, confidential information, know-how and other intellectual property used in the Business of Pledgor now or in the future and all renewals, modifications, derivatives and improvements relating thereto (collectively, the "Trade Secrets"); (ii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the Trade Secrets, including license fees and royalties under license and other agreements; (iii) all claims, causes of action, damages and recoveries for past, present and future infringements or unauthorized use of any of the Trade Secrets and all rights arising therefrom and pertaining thereto; (iv) all rights corresponding to the Trade Secrets throughout the world; (v) all general intangibles (as defined in the UCC) and all intangible intellectual property or other similar property of Pledgor of any kind or nature, whether now owned or

hereafter acquired or developed, associated with or arising out of the Trade Secrets (including without limitation all license, distributorship and/or franchise agreements and rights under any Existing Interests) and not otherwise described herein; (vi) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (vii) all Proceeds and products of any and all of the foregoing (all of the foregoing, collectively, the "Trade Secret Collateral").

(c) Copyright Collateral. (i) All published and unpublished works of authorship that Pledgor owns or uses in its Business or will in the future adopt and so use (including all advertising and promotional materials, franchise agreements and franchise operation manuals) all original and derivative works of authorship and works protectable by copyright that are presently or in the future may be, owned, created, authored, acquired or used (pursuant to a license or otherwise) by Pledgor or by its employees, independent contractors, third parties or acquired by Pledgor, all of Pledgor's proprietary object code, source code, source data files and documentation in any way related to the Business and any modifications and derivative works related thereto, all copyright registrations and applications for copyright registration that previously have been or may hereafter be issued thereon or applied for in the U.S. or anywhere in the world, all registrations resulting from such copyright applications, and all renewals, modifications, extensions, derivative works and collective works thereof or related to any of the foregoing, throughout the world, together with all copyright licenses held by Pledgor, and all common law rights, copyrights, rights of authorship and moral rights related to any of the foregoing, including without limitation, any of the foregoing identified on Schedule "A" hereto (as the same may be amended, modified or supplemented from time to time) (collectively, the "Copyrights"); (ii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the foregoing, including license fees and royalties under license and other agreements; (iii) all claims, causes of action, damages and recoveries for past, present and future infringements or unauthorized use of any of the Copyrights and all rights arising therefrom and pertaining thereto; (iv) all rights corresponding to the Copyrights throughout the world; (v) all general intangibles (as defined in the UCC) and all intangible intellectual property or other similar property of Pledgor of any kind or nature, whether now owned or hereafter acquired or developed, associated with or arising out of any of the Copyrights (including without limitation all license, distributorship and/or franchise agreements and rights under any Existing Interests) and not otherwise described herein; (vi) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (vii) all Proceeds and products of any and all of the foregoing (all of the foregoing, collectively, the "Copyright Collateral").

(d) Patent Collateral. (i) All patents and patent applications (including, without limitation, the inventions, devices, specifications and improvements described and claims therein) filed in the U.S. or in any other country, owned, held or used by Pledgor in whole or in part, and all patent and invention disclosures related thereto, together with all reissuances, divisions, continuations, continuations-in-part, renewals, extensions, re-examinations, supplementary protection certificates, modifications, derivatives and improvements thereof and the inventions disclosed therein, and all new or separate patents that may be issued in connection with the foregoing, and all other inventions (whether patentable or unpatentable, whether or not reduced to practice or developed alone or jointly with others), and together with and including all patent licenses held by Pledgor, and all other rights, including the right to make, use, license, sell, exploit and otherwise transfer the inventions disclosed therein, including without limitation, any of the foregoing identified on Schedule "A" hereto (as the same may be amended, modified

or supplemented from time to time) (collectively the "Patents"); (ii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the Patents, including license fees and royalties under license and other agreements; (iii) all claims, causes of action, damages and recoveries for past, present and future infringements thereof or unauthorized use of any of the Patents and all rights arising therefrom and pertaining thereto; (iv) all rights corresponding to the Patents throughout the world; (v) all general intangibles (as defined in the UCC) and all intangible intellectual property or other similar property of Pledgor of any kind or nature, whether now owned or hereafter acquired or developed, associated with or arising out of any of the Patents (including without limitation all license, distributorship and/or franchise agreements and rights under any Existing Interests) and not otherwise described herein; (vi) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (vii) all products and Proceeds of any and all of the foregoing (all of the foregoing, collectively, the "Patent Collateral").

3. Obligations Secured. This Agreement and the security interest granted by this Agreement secure (in such order of priority as Lender may determine, in its sole discretion) the payment, performance, observance and satisfaction by Pledgor of all of its obligations under all of the following and all modifications, amendments, renewals, replacements and extensions of each of them (collectively, the "Obligations"): (a) the Loan Documents; (b) all obligations of Pledgor under the Pledgor Documents; (c) all other indebtedness and obligations of Pledgor to Lender whether currently existing or hereafter arising; (d) all amounts that Lender may advance or spend for the maintenance or preservation of the Collateral, and any other expenditures that Lender may make pursuant to the provisions of this Agreement or for the benefit of Pledgor; and (e) any of the foregoing that arises after the filing of a petition by or against Pledgor pursuant to the United States Bankruptcy Code, even if the Obligations do not accrue because of the automatic stay under Bankruptcy Code Section 362 or otherwise.

4. Further Assurances; Appointment of Lender As Attorney-In-Fact. Pledgor, at its expense, shall execute and deliver, or cause to be executed and delivered, to Lender any and all documents and instruments, in form and substance reasonably satisfactory to Lender, and take any and all action, which Lender may reasonably request from time to time, in order to evidence, protect, maintain, perfect or continue the security interest of Lender in the Collateral, to effectuate or enforce the rights granted to Lender hereunder, or to otherwise carry out the purposes and intent of this Agreement. Without limiting the foregoing, Pledgor authorizes Lender to file financing statements and such other instruments as may be necessary or desirable to perfect security interests created hereby in all states, counties and other jurisdictions as Lender may elect, without Pledgor's signature if permitted by law, describing the Collateral. Pledgor hereby irrevocably appoints Lender as its true and lawful attorney-in-fact with full power of substitution in the place and stead of Pledgor and in the name of Pledgor, Lender or otherwise, from time to time in Lender's discretion to do the following: (a) to sign or endorse the name of Pledgor on all or any of such documents or instruments and perform all other acts that Lender reasonably deems necessary or advisable in order to perfect or continue perfection, maintain the priority or enforceability of or provide notice of Lender's security interest in the Collateral; (b) to execute any and all other applications, documents and instruments and to perform any and all acts and things for and on behalf of Pledgor, which Lender may reasonably deem necessary or advisable to maintain, preserve and protect the Collateral and to accomplish the purposes of this Agreement, including (i) to defend, settle, adjust or institute any action, suit or proceeding with

respect to the Collateral, (ii) to assert or retain any rights under any license, distribution or franchise agreement for or with respect to any of the Collateral and (iii) to execute any and all applications, documents, papers and instruments for Lender to use the Collateral, to grant or issue any exclusive or non-exclusive license with respect to any Collateral, and to assign, convey or otherwise transfer title in or dispose of the Collateral; and (c) to take any other actions with respect to the Collateral, consistent with the terms of this Agreement, as Lender deems reasonably necessary or in the best interest of Lender. The power of attorney set forth in this Section 4 is coupled with an interest and is irrevocable so long as this Agreement shall be in effect. Pledgor hereby ratifies all that Lender shall lawfully do or cause to be done by virtue hereof.

5. Covenants. Pledgor covenants and agrees that, to the best of its ability, as long as this Agreement shall be in effect:

(a) Pledgor shall use commercially reasonable efforts to (i) actively police and defend the Collateral, file and prosecute lawsuits, interference, opposition and cancellation proceedings, and take such other actions as necessary to protect the strength of and rights in the Collateral, (ii) protect, defend and maintain the validity and enforceability of the Collateral, (iii) ascertain or discover any infringements or violations of the Collateral and promptly advise Lender in writing of any infringements or violations detected, and (iv) not allow any Collateral to be abandoned, forfeited or dedicated to the public without the consent of Lender which shall not be unreasonably withheld; provided, however, Pledgor may abandon and/or forfeit any application, filing and/or registration in any foreign (non-United States) jurisdiction but only after Pledgor has reasonably determined that such abandonment and/or forfeiture will not result in a Material Adverse Effect. Lender shall have the right, but not the obligation, to take, at Pledgor's sole expense, in its own name or in Pledgor's name or in the names of the parties jointly any actions that Pledgor is required to take under this section or other provisions of this Agreement, but which Pledgor fails to take. Pledgor shall prosecute any infringement or violation of the Collateral to protect the Collateral as required by this Agreement, giving due consideration to value, importance, cost and opinion of counsel as to such action. If Pledgor decides not to prosecute an infringement or violation of the Collateral, Pledgor shall promptly notify Lender in writing explaining the facts and reasons why Pledgor has decided not to pursue such infringement or violation. If Lender reasonably determines that such infringement or violation must be prosecuted in order to protect Lender's interest in the Collateral, Lender shall so notify Pledgor in writing and Pledgor shall thereafter promptly prosecute such infringement or violation at Pledgor's expense;

(b) Pledgor shall promptly, upon its becoming aware thereof, notify Lender in writing of the existence or receipt of (i) any claim, dispute, lawsuit, arbitration, opposition, cancellation or interference proceeding, or other proceeding that in any way involves or relates to any of the Collateral, (ii) any adverse determination in or with respect to any of the pending or future applications for registration or registrations of any of the Collateral, and/or (iii) any adverse determination in or with respect to any lawsuits or other proceedings regarding the Collateral or regarding Pledgor's claim of ownership in or right to use any of the Collateral; Pledgor shall promptly provide to Lender any information with respect thereto required from time to time by Lender;

(c) Pledgor shall renew, preserve and maintain all Patents, Trademarks, Copyrights, Trade Secrets and other Collateral in a reasonable and timely manner, including without limitation filing all required affidavits and other documents and paying all necessary maintenance and other fees; provided, however, Pledgor may forego renewal, preservation and/or maintenance of any of the foregoing in any foreign (non-United States) jurisdiction but only after Pledgor has reasonably determined that such abandonment and/or forfeiture will not result in a Material Adverse Effect.

(d) Pledgor shall not sell, pledge, encumber, lien, hypothecate, assign, license, franchise, distribute or otherwise dispose of any rights in any of the Patents, Trademarks, Copyrights, Trade Secrets or other Collateral to any third party, in the U.S. or internationally, without the express, written consent of Lender, which consent shall not be unreasonably withheld by Lender;

(e) Lender shall have no obligation or responsibility to preserve, protect or defend the Collateral and Pledgor shall at its own expense protect, defend and maintain the same as required by this Agreement or specifically by Lender from time to time in its sole discretion;

(f) Pledgor shall use commercially reasonable efforts to prosecute diligently any Patent, Copyright, Trademark or other intellectual property application pending as of the date hereof or hereafter. Pledgor shall notify Lender in writing of any such applications filed and/or registrations received for any of the Patents, Trademarks, Copyrights or other Collateral, and the parties shall amend this Agreement, any assignments, UCC-1 Financing Statements, Memorandum of Security Agreement or other document to reflect such applications and registrations. Pledgor shall diligently file and prosecute applications for registration for all major variations and improvements to the Trademarks, Copyrights and Patents, including derivative and collective marks and works upon their adoption and use;

(g) Pledgor shall employ notices and proprietary markings in compliance with applicable legal requirements or as permitted to maximize the protection and enforcement of the Collateral;

(h) If Pledgor fails to comply with any of its covenants or agreements herein, Lender may do so in Pledgor's name or in Lender's name, at Pledgor's expense, and Pledgor shall reimburse Lender for all expenses, including reasonable attorney's fees and costs, incurred by Lender in protecting, defending and maintaining the Collateral;

(i) Pledgor shall not enter into any agreement (for example, a license agreement, distribution agreement, joint development agreement, franchise agreement or work for hire agreement) that would allow actual or potential Collateral to become all or partly owned by any other Person, or that is inconsistent with Pledgor's obligations under this Agreement, without Lender's prior written consent;

(j) Pledgor shall not take any action, or permit any action to be taken by others subject to its control, including licensees, joint venture partners, franchisees, vendors, or joint developers, or fail to take any action, if doing so or not doing so would impair the title to, or validity or enforceability of the Collateral and/or of Lender's interest in the Collateral;

(k) Pledgor shall permit Lender, at any reasonable time, upon reasonable frequency, and upon reasonable prior written notice, to inspect Pledgor's premises and to examine Pledgor's books, records, operations, and use and protection of the Patents, Trademarks, Copyrights, Trade Secrets and other Collateral, and permit Lender to make and retain copies of any of the Collateral and of such books and records in order to protect its interest in the Collateral;

(l) Pledgor shall, promptly after executing this Agreement, to the extent not previously provided to Lender, provide to Lender a copy of the written agreements between Pledgor and the Existing Interest Holders;

(m) Pledgor shall pay when due all taxes and assessments against the Collateral and all claims and demands arising from Pledgor's ownership or use of the Collateral, and will not cause or permit any Lien to be imposed on or to exist against the Collateral;

(n) Pledgor shall make no change to its organization status or existence, state of incorporation, corporate identification number, or name, nor merge into or consolidate with any other Person, in each case without providing Lender at least thirty (30) days' prior written notice; and

(o) Pledgor shall, with respect to Collateral consisting of rights in or under agreements, contracts, accounts, instruments, leases, permits, licenses, franchises, and the like, now existing or hereafter acquired or entered into, including any license agreements made by Pledgor (collectively, "Third Party Agreements") do the following:

(i) except with respect to Third Party Agreements of inconsequential value, the breach or loss of which could have no material adverse effect on Pledgor, the Business or any of the remaining Collateral, Pledgor will, at its sole cost and expense (a) perform and satisfy every obligation and condition of the Third Party Agreements to be performed or satisfied by Pledgor; (b) give prompt notice to Lender of any notice of default given or received by Pledgor under any Third Party Agreements, together with a copy of any such notice of default; (c) enforce, short of termination, the performance and satisfaction of every obligation and condition of the Third Party Agreements to be performed or satisfied by the other parties to the Third Party Agreements; and (d) appear in and defend any action arising from or relating to the Third Party Agreements or the obligations of any party under any Third Party Agreement;

(ii) except with respect to Third Party Agreements of inconsequential value, the breach or loss of which could have no material adverse effect on Pledgor, the Business or any of the remaining Collateral, Pledgor will not, without Lender's prior written consent, take any action to (a) terminate or amend any Third Party Agreements; (b) waive or release the parties to any Third Party Agreements from any obligation or condition to be performed or satisfied by such parties; (c) assign, transfer, pledge or otherwise encumber any of its rights in any Third Party Agreements, absolutely or for security; or (d) revoke or countermand, or attempt or purport to revoke or countermand, the irrevocable authorizations and instructions set forth in Subsection (iii) below. Any such purported action by Pledgor without Lender's prior written consent will be void and will constitute a default under this Agreement;

(iii) Pledgor hereby irrevocably authorizes and instructs every present and future party under every Third Party Agreement, upon demand by Lender, to pay and perform all of such party's obligations directly and only to Lender, to recognize and accept Lender as the holder of all of Pledgor's rights and benefits under the Third Party Agreement for all purposes, and to accept any payment or performance by Lender of Pledgor's obligations under the Third Party Agreement that Lender may elect to tender. No such party shall have any duty to investigate the validity or accuracy of any such demand by Lender. Each such party shall be relieved of any liability to Pledgor for payment or performance under a Third Party Agreement to the extent that such party has paid or performed to Lender, pursuant to demand of Lender, even if it is later determined that Lender's demand for payment or performance was invalid. Lender shall have the right at any time to enforce Pledgor's rights against every present and future party under every Third Party Agreement (including without limitation the account debtors and obligors); and

(iv) Lender is not obligated to perform any obligations of Pledgor under any Third Party Agreement unless Lender so elects, and Pledgor shall remain liable under every Third Party Agreement to the same extent as if this Agreement had not been executed. The exercise by Lender of any rights and remedies under this Agreement shall not release Pledgor from any of its duties or obligations under any Third Party Agreement.

6. Representations and Warranties. Pledgor represents, warrants and covenants, to the best of its knowledge, that now and in the future during the pendency of this Agreement and until the Obligations are satisfied in full as follows:

(a) Schedule "A" sets forth a true, correct and complete list of all of the existing Trademarks, Copyrights and Patents that are registered or for which any application for registration has been filed with the PTO or any corresponding or similar office of any other jurisdiction and that are owned and used by Pledgor, in whole or in part;

(b) Schedule "B" which sets forth the Existing Interests and Existing Interest Holders, sets forth a true, correct and complete list of all Existing Interest Holders to whom Pledgor has pledged, licensed, franchised or distributed any of the Collateral and all of the agreements giving rise to the Existing Interests;

(c) The Collateral and all portions thereof is subsisting, has not been adjudged invalid or unenforceable in whole or in part, is not currently being challenged in any way, and there are no pending or threatened claims, litigation, proceedings or other investigations regarding any of the Collateral. Except as otherwise disclosed to Lender in writing prior to the date of this Agreement, none of the Collateral has lapsed or expired or been abandoned or allowed to fall into the public domain;

(d) All maintenance, renewal and other fees required to be paid on account of any Collateral have been timely paid for maintaining such Collateral in force, and all affidavits of use required to be filed with respect to any Trademarks have been timely filed to maintain such Trademarks in force;

(e) Pledgor owns the entire worldwide right, title and interest in and to the Collateral and each portion thereof free and clear of any Liens and rights of others, except for the Liens and rights granted by Pledgor pursuant to this Agreement and the Existing Interests of the Existing Interest Holders (provided Lender's security interest in the Collateral is senior in priority to the Existing Interests); and each such license, franchise or distribution agreement giving rise to the Existing Interests is in full force and effect, and other than parties to such license, franchise or distribution agreements, to Pledgor's knowledge, no other Person has any rights to or in any of the Collateral;

(f) Pledgor has the unqualified right, power and authority to pledge and grant to Lender a first priority security interest in all of the Collateral, and execute, deliver and perform its obligations in accordance with the terms of this Agreement, without the consent or approval of any other Person except as already obtained; this Agreement has been fully authorized, executed and delivered, and constitutes a legal, valid and binding agreement of Pledgor enforceable in accordance with its terms; and the execution, delivery and performance by Pledgor of this Agreement do not violate any provision of law or the articles of incorporation or bylaws of Pledgor or result in a breach of or constitute a default under any contract, obligation, indenture or other instrument to which Pledgor is a party or by which Pledgor may be bound;

(g) Pledgor has continually used in commerce all Trademarks once use of such has commenced;

(h) Pledgor has in place a commercially reasonable system to protect its Trade Secrets. Pledgor has taken and will continue to take all commercially reasonable steps to protect the confidentiality of all Trade Secrets;

(i) Neither Pledgor nor any of the Existing Interest Holders are in breach or default of any of the Third Party Agreements and no event has occurred which with notice or lapse of time would constitute a breach or default, or permit the termination or modification of any of the Third Party Agreements;

(j) Pledgor has not transferred, pledged or otherwise encumbered any of its rights or interests in or under any of the Third Party Agreements;

(k) Pledgor, the Collateral, and products sold or services rendered by Pledgor, and/or any processes used by Pledgor in its Business do not infringe or violate any third party's intellectual property rights, and no claim has been made that the use of any of the Collateral or any products or services incorporating any of the Collateral constitutes an infringement or violation of any third party's intellectual property rights. Pledgor has not engaged in any conduct that would constitute unfair competition, unfair trade practices, defamation or otherwise would conflict with another Person's intellectual property rights or other rights. To Pledgor's knowledge, no third parties are infringing upon or violating any of the rights in any of the Collateral;

(l) Schedule "A" sets forth a true, accurate and complete list of all material technologies and proprietary rights of Pledgor that are necessary to operate Pledgor's Business;

(m) Pledgor has not agreed with any other Person not to sue or otherwise enforce any legal or equitable rights regarding the Collateral; and

(n) Pledgor shall undertake all reasonable measures to cause its employees, agents and independent contractors to assign to Pledgor all rights in and to any Collateral in which Pledgor has or may subsequently acquire any right or interest.

7. Event of Default. It shall be an "Event of Default" hereunder if Pledgor shall fail to perform or comply with any of the provisions of this Agreement, or if any representation or warranty made herein shall be false or misleading in any material respect, or if an "Event of Default" shall exist under and as defined in any one or more of the Loan Documents. Pledgor expressly acknowledges and agrees that this Section 7 is intended to and does hereby cross-default this Agreement with the Pledgor's obligations under the Loan Documents, such that the occurrence of any Event of Default under any one or more of the Loan Documents shall constitute an immediate Event of Default hereunder. Lender shall provide Pledgor a written notice of an Event of Default. Notwithstanding anything to the contrary in this paragraph, it shall not be an "Event of Default" if Pledgor shall rectify the default to the satisfaction of Lender within five (5) business days after receipt of such notice for an Event of Default that involves a monetary Event of Default and within ten (10) business days after receipt of such notice for any other (non-monetary) Event of Default; provided, however, the foregoing shall not be construed to create an additional cure period for an Event of Default in addition to the cure rights set forth in the other Loan Documents.

8. Remedies. From and after the occurrence of an Event of Default, for so long as such Event of Default remains uncured, Lender shall have all rights and remedies available to it under this Agreement, under the Loan Documents and under applicable law (which rights and remedies are cumulative). Pledgor agrees that such rights and remedies include the right of Lender as a secured party to sell or otherwise dispose of the Collateral after default, pursuant to the UCC. Pledgor agrees that, in addition to its other rights, Lender shall at all times have such worldwide, royalty-free, exclusive, transferable, licenses (including the right to sublicense) for any Collateral that is reasonably necessary to permit the exercise of any of Lender's rights or remedies hereunder, including upon or after the occurrence of an Event of Default with respect to any assets of Pledgor in which Lender has a security interest, including Lender's rights to sell inventory, tooling, equipment or packaging which is owned or acquired by Pledgor (or its successor, assignee or trustee in bankruptcy). In addition to and without limiting any of the foregoing, upon the occurrence of an Event of Default, Lender shall have the right, but not the obligation, to bring suit or to take such other action as Lender deems necessary or advisable, in the name of Pledgor or Lender, to enforce its rights under this Agreement or to enforce or protect any of the Collateral, in which event Pledgor shall, at the request of Lender, do any and all lawful acts and execute any and all documents required by Lender in aid of such enforcement. Pledgor acknowledges and agrees that Lender may execute and acknowledge any and all such documents pursuant to the power of attorney granted to Lender hereunder but shall have no fiduciary duties to Pledgor thereunder to the maximum extent permitted by applicable law.

9. Indemnity. Pledgor shall indemnify, defend and hold Lender and its officers, directors, employees, agents, and affiliates (collectively, the "Indemnitees" and individually an "Indemnitee") harmless from and against any and all other liabilities, obligations, losses,

damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatever (including, without limitation, the reasonable fees and disbursements of counsel for such Indemnitees in connection with any investigative, administrative or judicial proceeding commenced or threatened, whether or not such Indemnitees are designated parties thereto) that may be imposed on, incurred by, or asserted against the Indemnitees, in any manner relating to or arising out of the Agreement or out of any undertaking or proceeding related to any of the transactions contemplated hereby or any act, omission, event or transaction related or attendant thereto, including amounts paid in settlement, court costs, and the fees and expenses of counsel (collectively, the "Indemnified Liabilities"); *provided, however*, that Pledgor shall have no obligation to an Indemnitee hereunder with respect to Indemnified Liabilities arising from the negligence or willful misconduct of that Indemnitee.

10. Miscellaneous.

(a) Termination. The security interest in the Collateral granted hereunder shall remain in full force and effect until the Obligations are satisfied in full and the Loan Documents and any commitment to extend any financial accommodation thereunder have been terminated. At such time, Lender shall, within five (5) business days, execute and deliver to Pledgor, or to a third party upon Pledgor's instructions, for filing with the appropriate government entity in the U.S. or elsewhere and in each office in which any financing statement pertaining to the security interest granted hereby may have been filed: (i) documentation in accordance with the rules and regulations of such office, (ii) termination statements under the UCC, and (iii) any other documentation reasonably requested by Pledgor, all as may be necessary to release Lender's interest in the Collateral.

(b) Governing Law; Venue; Jury Waiver. If there is a lawsuit or other proceeding, Pledgor agrees upon Lender's request to submit to the jurisdiction of the courts of San Diego County, California. To the extent permitted under applicable laws, Lender and Pledgor hereby waive the right to any jury trial in any action, proceeding or counterclaim brought by Lender or Pledgor against the other, and each waive any right to object to or contest the venue or jurisdiction selected by Lender. This Agreement will be governed by, construed and enforced in accordance with federal law and the laws of the State of California.

(c) Entire Agreement. This Agreement and that certain Security Agreement (Blanket) dated as of the date hereof, constitutes the entire agreement between the parties regarding the subject matter hereof, and supersedes all prior or contemporaneous understandings or agreements, whether oral or written regarding the subject matter hereof. No alteration or amendment to this Agreement shall be effective unless given in writing and signed by the party or parties sought to be charged or bound by the alteration or amendment.

(d) Notice. All notices, requests, demands and other communications required or permitted to be given hereunder shall be in writing and shall be given personally, sent by facsimile transmission, electronic mail, prepaid air courier or certified, registered or express mail, postage prepaid. Any such notice shall be deemed to have been given or made for all purposes: (a) in any event, upon actual receipt by the recipient; (b) upon confirmation receipt (or oral confirmation) that the communication was successfully sent to the recipient if sent by facsimile or other electronic communication; (c) one day after being sent, when sent by

professional overnight courier service; or (d) three (3) business days after posting when sent by registered or certified mail. All notices, communications and/or payments should be addressed to the party for whom intended, as follows:

To Lender: VINDRAUGA CORPORATION
1565 Hotel Circle South, Suite 310
San Diego, California 92108
Attn: James R. Wade
Facsimile: (619) 220-8112

To Pledgor: RIDGE DIAGNOSTICS, INC.
4225 Executive Square, Suite 600
La Jolla, California 92037
Attn: Lonna J. Williams
Facsimile: () -

(e) Costs and Expenses. Pledgor agrees to pay upon demand all of Lender's costs and expenses, including Lender's attorneys' fees and Lender's legal expenses, incurred in connection with the preparation, execution, enforcement, modification and collection of this Agreement. Lender may hire or pay someone else to help collect the Obligations and to enforce this Agreement, and Pledgor shall pay the costs and expenses of such collection and enforcement. Costs and expenses include Lender's attorneys' fees and Lender's legal expenses whether or not there is a lawsuit, including attorneys' fees and legal expenses for bankruptcy proceedings (including efforts to modify or vacate any automatic stay or injunction), appeals, and any anticipated post-judgment collection services. Pledgor also shall pay all court costs and such additional fees as may be directed by the court.

(f) Severability. If a court of competent jurisdiction finds any provision of this Agreement to be illegal, invalid, or unenforceable as to any circumstance, that finding shall not make the offending provision illegal, invalid, or unenforceable as to any other circumstance. If feasible, the offending provision shall be considered modified so that it becomes legal, valid and enforceable. If the offending provision cannot be so modified, it shall be considered deleted from this Agreement. Unless otherwise required by law, the illegality, invalidity, or enforceability of any provision of this Agreement shall not affect the legality, validity or enforceability of any other provision of this Agreement.

(g) Successors and Assigns. All covenants and agreements contained by or on behalf of Pledgor shall bind Pledgor's successors and assigns and shall inure to the benefit of Lender and its successors and assigns. Pledgor shall not, however, have the right to assign Pledgor's rights under this Agreement or any interest therein, without the prior written consent of Lender.

(h) Survival. Pledgor understands and agrees that in making the Loan and other financial accommodations set forth in the Loan Documents, Lender is relying on all representations, warranties, and covenants made by Pledgor in this Agreement or in any certificate or other instrument delivered by Pledgor to Lender under this Agreement. Pledgor further agrees that regardless of any investigation made by Lender, all such representations,

warranties and covenants will survive the making of the Loan and other financial accommodations set forth in the Loan Documents, shall be continuing in nature, and shall remain in full force and effect until such time as all Obligations shall be paid and satisfied in full, or until this Agreement shall be terminated in the manner provided above, whichever is the last to occur.

(i) Time is of the Essence. Time is of the essence in the performance of this Agreement.

(j) Waiver. Lender shall not be deemed to have waived any right under this Agreement unless such waiver is given in writing and signed by Lender. No delay or omission on the part of Lender in exercising any right shall operate as a waiver of such right or any other right. A waiver by Lender of a provision of this Agreement shall not prejudice or constitute a waiver of Lender's right otherwise to demand strict compliance with that provision or any other provision of this Agreement. No prior waiver by Lender nor any course of dealing between Lender and Pledgor shall constitute a waiver of any of Lender's rights or Pledgor's obligations as to any future transactions. Whenever the consent of Lender is required under this Agreement, the granting of such consent by Lender in any instance shall not constitute continuing consent in subsequent instances where such consent is required and in all cases such consent may be granted or withheld in the sole discretion of Lender.

(k) Counterparts. This Agreement may be executed in any number of counterparts and by different parties hereto and separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute but one and the same agreement.

* * * * *

IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first written above.

PLEDGOR:

RIDGE DIAGNOSTICS, INC.,
a Delaware corporation

By: Donna J. Williams
Name: Donna J. Williams
Its: CEO

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT


CIVIL CODE § 1189

State of California

County of San Diego

On 11/6/2013 before me, C.M. Parenteau, Notary Public

personally appeared LONNA JEAN WILLIAMS



who proved to me on the basis of satisfactory evidence to be the person~~(s)~~ whose name~~(s)~~ is/~~are~~ subscribed to the within instrument and acknowledged to me that ~~he~~/she/~~they~~ executed the same in his/~~her~~/their authorized capacity~~(ies)~~, and that by his/~~her~~/their signature~~(s)~~ on the instrument the person~~(s)~~, or the entity upon behalf of which the person~~(s)~~ acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature: C.M. Parenteau

Place Notary Seal Above

OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

Description of Attached Document

Title or Type of Document: IP Security Agreement for Ridge Diagnostics, Inc.

Document Date: _____ Number of Pages: _____

Signer(s) Other Than Named Above: _____

Capacity(ies) Claimed by Signer(s)

Signer's Name: Lonna Jean Williams

☒ Corporate Officer — Title(s): CEO

☐ Individual

☐ Partner — ☐ Limited ☐ General

☐ Attorney in Fact

☐ Trustee

☐ Guardian or Conservator

☐ Other: _____

Signer's Name: _____

☐ Corporate Officer — Title(s): _____

☐ Individual

☐ Partner — ☐ Limited ☐ General

☐ Attorney in Fact

☐ Trustee

☐ Guardian or Conservator

☐ Other: _____

Signer Is Representing: Ridge Diagnostics, Inc.

Signer Is Representing: _____

Schedule A to the Intellectual Property Security Agreement

Ridge Diagnostics, Inc

Intellectual Property Status List

As at 4 Oct 2013

F&R Ref.	Country	Serial No.	Filing Date	Pub. No.	Pub. Date	Patent No.	Issue Date	Status
Molecule Interaction Measurement Chip and System								
20436-0004P01	US	60/748,824	9-Dec-2005	-	-	-	-	Expired (converted to PCT)
20436-0004US1	US	12/305,950	19-Dec-2008	2010-0144052	10-Dec-2010	-	-	Pending
20436-0004WO1	WIPO	PCT/US2006/047244	11-Dec-2006	WO 2007/067819	14-Jun-2007	-	-	Expired (national phase)
Molecular Interaction Detection Chip and Fabrication Process								
20436-0005P01	US	60/784,322	21-Mar-2006	-	-	-	-	Expired (converted to PCT (0004WO1))
Precision Molecule Interaction Measurement System and Method								
20436-0006P01	US	60/796,585	1-May-2006	-	-	-	-	Expired (converted to PCT (0004WO1))
Quantitative Diagnostic Methods Using Multiple Parameters								
20436-0007001	US	11/850,550	5-Sep-2007	-	-	8,158,374	17-Apr-2012	Issued
20436-0007002	US	13/446,382	13-Apr-2012	2012-0289422	15-Nov-2012	8,450,077	28-May-2013	Issued
20436-0007003	US	13/903,346	28-May-2013	-	-	-	-	Pending
20436-0007P01	US	60/824,471	5-Sep-2006	-	-	-	-	Expired (converted to utility)
Diagnostics with multiple parameters -algorithm and methods								
20436-0008P01	US	60/910,217	5-Apr-2007	-	-	-	-	Expired (converted to utility (0007001))
Diagnostics with multiple parameters -algorithm and methods								
20436-0009P01	US	61/033,726	4-Mar-2008	-	-	-	-	Expired (converted to PCT)
20436-0009WO1	WIPO	PCT/US2009/036084	4-Mar-2009	WO 2009/111595	11-Sep-2009	-	-	Expired (national phase)
20436-0009CA1	Canada	2717763	4-Mar-2009	-	-	-	-	Pending
20436-0009CN1	China	200980115931.3	4-Mar-2009	CN10203755A	27-Apr-2011	-	-	Pending
20436-0009EP1	Europe	9717234	4-Mar-2009	2329260	8-Jun-2011	-	-	Pending
20436-0009JP1	Japan	2010-549863	4-Mar-2009	2011-518318	23-Jun-2011	-	-	Pending
20436-0009US1	US	12/921,349	4-Mar-2009	2011-0245092	6-Oct-2011	-	-	Pending
Combinations of Selected Biomarkers for Diagnosing Depression Disorders								
20436-0010P01	US	61/033,721	4-Mar-2008	-	-	-	-	Expired (converted to PCT (0009WO1))
Monitoring Depression Disorders Based on Hypothalamic-Pituitary-Adrenal (HPA) Axis Biomarkers								
20436-0011P01	US	61/033,731	4-Mar-2008	-	-	-	-	Expired (converted to PCT (0009WO1))
Inflammatory Biomarkers for Monitoring Depressive Disorders								
20436-0012P01	US	61/036,013	12-Mar-2008	-	-	-	-	Expired (converted to PCT)
20436-0012WO1	WIPO	PCT/US2009/036833	11-Mar-2009	WO 2009/114627	17-Sep-2009	-	-	Expired (national phase)
20436-0012CA1	Canada	2718273	11-Mar-2009	-	-	-	-	Pending
20436-0012CN1	China	200980116135.1	11-Mar-2009	CN 102016907A	13-Apr-2011	-	-	Pending
20436-0012EP1	Europe	9718958.3	11-Mar-2009	2272044	12-Jan-2011	-	-	Pending
20436-0012HK1	Hong Kong	11107199.1	12-Jul-2011	1153282	23-Mar-2012	-	-	Pending
20436-0012JP1	Japan	2010-550839	11-Mar-2009	2011-520095	14-Jul-2011	-	-	Pending
20436-0012US1	US	12/922,365	11-Mar-2009	2011-0269633	3-Nov-2011	-	-	Pending
Human Biomarker Hypermapping for Depressive Disorders								
20436-0013P01	US	61/105,641	15-Oct-2008	-	-	-	-	Expired (converted to PCT and utility)
20436-0013001	US	12/579,733	15-Oct-2009	2010-0100333	22-Apr-2010	-	-	Pending
20436-0013WO1	WIPO	PCT/US2009/060895	15-Oct-2009	WO 2007/030475	15-Mar-2007	-	-	Expired (national phase)
20436-0013CA1	Canada	2740736	15-Oct-2009	-	-	-	-	Pending

PATENT

REEL: 038831 FRAME: 0176

20436-0013CN1	China	200980147037.4	15-Oct-2009	CN 102257157A	23-Nov-2011	-	-	Pending
20436-0013EP1	Europe	9821274.9	15-Oct-2009	2337866	29-Jun-2011	-	-	Pending
20436-0013HK1	Hong Kong	12105066.4	15-Oct-2009	1164379	21-Sep-2012	-	-	Pending
20436-0013JP1	Japan	2011-0532262	15-Oct-2009	2012-506053	8-Mar-2012	-	-	Pending
Combinations of Metabolic Syndrome and HPA Axis Biomarkers for Monitoring Major Depressive Disorder								
20436-0014P01	US	61/115,710	18-Nov-2008	-	-	-	-	Expired (converted to PCT and utility)
20436-0014001	US	12/620,831	18-Nov-2009	2010-0136700	3-Jun-2010	8,440,418	14-May-2013	Issued
20436-0014002	US	13/892,714	13-May-2013	-	-	-	-	Pending
20436-0014WO1	WIPO	PCT/US2009/064967	18-Nov-2009	WO 2010/059709	27-May-2010	-	-	Expired (national phase)
20436-0014CA1	Canada	2744151	18-Nov-2009	-	-	-	-	Pending
20436-0014CN1	China	200980153799.5	18-Nov-2009	CN 102301234A	28-Dec-2011	-	-	Pending
20436-0014EP1	Europe	9828159.5	18-Nov-2009	2356453	17-Aug-2011	-	-	Pending
20436-0014HK1	Hong Kong	12106344.6	18-Nov-2009	1165554	5-Oct-2012	-	-	Pending
20436-0014JP1	Japan	2011-537577	18-Nov-2009	2012-509480	19-Apr-2012	-	-	Pending
Biomarker Panels for Stratifying and Monitoring Major Depressive Disorder								
20436-0015P01	US	61/298,443	26-Jan-2010	-	-	-	-	Expired (converted to PCT and utility)
20436-0015001	US	13/014,413	26-Jan-2011	2011-0213219	1-Sep-2011	-	-	Pending
20436-0015WO1	WIPO	PCT/US2011/022573	26-Jan-2011	WO 2011/094308	4-Aug-2011	-	-	Expired (national phase)
20436-0015CA1	Canada	2788315	26-Jan-2011	-	-	-	-	Pending
20436-0015CN1	China	201180011737.8	26-Jan-2011	CN 102884428A	16-Jan-2013	-	-	Pending
20436-0015EP1	Europe	11737575.8	26-Jan-2011	2529222	5-Dec-2012	-	-	Pending
20436-0015JP1	Japan	2012-551263	26-Jan-2011	2013-518287	20-May-2013	-	-	Pending
Biomarkers for Monitoring Treatment of Neuropsychiatric Diseases								
20436-0016P01	US	61/165,662	1-Apr-2009	-	-	-	-	Expired (converted to PCT and utility)
20436-0016001	US	12/753,022	1-Apr-2010	2010-0280760	4-Nov-2010	-	-	Pending
20436-0016WO1	WIPO	PCT/US2010/029720	1-Apr-2010	WO 2010/0115061	7-Oct-2010	-	-	Expired (national phase)
20436-0016CA1	Canada	2757518	1-Apr-2010	-	-	-	-	Pending
20436-0016CN1	China	201080022306.7	1-Apr-2010	CN 102483398A	30-May-2012	-	-	Pending
20436-0016EP1	Europe	10759446.7	1-Apr-2010	2414824	8-Feb-2012	-	-	Pending
20436-0016HK1	Hong Kong	12112408.7	1-Apr-2010	1171807	5-Apr-2013	-	-	Pending
20436-0016JP1	Japan	2012-503731	1-Apr-2010	2012-522995	27-Sep-2012	-	-	Pending
Biomarkers for Monitoring Treatment of Neuropsychiatric Diseases								
20436-0017P01	US	61/166,986	6-Apr-2009	-	-	-	-	Expired (converted to PCT and utility)
20436-0017001	US	12/754,770	6-Apr-2010	2010-0280562	4-Nov-2010	-	-	Pending
20436-0017WO1	WIPO	PCT/US2010/030104	6-Apr-2010	WO 2010/118035	14-Oct-2010	-	-	Expired (national phase)
20436-0017CA1	Canada	2757659	6-Apr-2010	-	-	-	-	Pending
20436-0017CN1	China	2010800252866.8	6-Apr-2010	CN 102460153A	16-May-2012	-	-	Pending
20436-0017EP1	Europe	10762304.3	6-Apr-2010	2417448	18-Feb-2012	-	-	Pending
20436-0017NK	Hong Kong	12111712.0	6-Apr-2010	1171081	15-Mar-2013	-	-	Pending
20436-0017JP1	Japan	2012-504782	6-Apr-2010	2012-523009	27-Sep-2012	-	-	Pending
Human Biomarker Test for Major Depressive Disorder								
20436-0018P01	US	61/798,910	15-Mar-2013	-	-	-	-	Pending
Biomarkers for Monitoring Treatment of Neuropsychiatric Diseases								
20436-0020P01	US	61/420,141	6-Dec-2010	-	-	-	-	Expired (converted to PCT and utility)
20436-0020001	US	13/312,553	6-Dec-2011	2012-0178118	7/12/2012	-	-	Pending
20436-0020WO1	WIPO	PCT/US2011/063522	6-Dec-2011	-	-	-	-	Expired (national phase)
20436-0020CA1	Canada	2820616	6-Dec-2011	-	-	-	-	Pending
20436-0020CN1	China	201180066505.2	6-Dec-2011	-	-	-	-	Pending
20436-0020EP1	Europe	11846638.2	6-Dec-2011	-	-	-	-	Pending
20436-0020JP1	Japan	unknown	6-Dec-2011	-	-	-	-	Pending
Trademarks								
Serial Number	Reg. Number	Word Mark	Check Status	Live/Dead	Registration Date			
85264705	4117318	RIDGE DIAGNOSTICS	TSDR	LIVE	3/27/2012			
85264659	4117317	RIDGE DIAGNOSTICS	TSDR	LIVE	3/27/2012			

Exhibit 2

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
RIDGE DIAGNOSTICS, INC.		11/07/2013	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	VINDRAUGA CORPORATION		
Street Address:	1565 HOTEL CIRCLE SOUTH, SUITE 310		
City:	SAN DIEGO		
State/Country:	CALIFORNIA		
Postal Code:	92108		
Entity Type:	CORPORATION: CALIFORNIA		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	4117318	RIDGE DIAGNOSTICS	
Registration Number:	4117317	RIDGE DIAGNOSTICS	
CORRESPONDENCE DATA			
Fax Number:	6197026858		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	619-685-3067		
Email:	hotaling@scmv.com		
Correspondent Name:	ANDREW D. BROOKS		
Address Line 1:	750 B STREET, SUITE 2100		
Address Line 2:	SELTZER CAPLAN MCMAHON VITEK		
Address Line 4:	SAN DIEGO, CALIFORNIA 92101		
NAME OF SUBMITTER:	ANDREW D. BROOKS		
Signature:	/Andrew D. Brooks/		
Date:	11/08/2013		

TRADEMARK

900271404

REEL: 005150 FRAME: 0861
 PATENT

REEL: 038831 FRAME: 0179

OP \$65.00 4117318

Total Attachments: 20

source=IP Security Agreement Ridge wSchedule A#page1.tif
source=IP Security Agreement Ridge wSchedule A#page2.tif
source=IP Security Agreement Ridge wSchedule A#page3.tif
source=IP Security Agreement Ridge wSchedule A#page4.tif
source=IP Security Agreement Ridge wSchedule A#page5.tif
source=IP Security Agreement Ridge wSchedule A#page6.tif
source=IP Security Agreement Ridge wSchedule A#page7.tif
source=IP Security Agreement Ridge wSchedule A#page8.tif
source=IP Security Agreement Ridge wSchedule A#page9.tif
source=IP Security Agreement Ridge wSchedule A#page10.tif
source=IP Security Agreement Ridge wSchedule A#page11.tif
source=IP Security Agreement Ridge wSchedule A#page12.tif
source=IP Security Agreement Ridge wSchedule A#page13.tif
source=IP Security Agreement Ridge wSchedule A#page14.tif
source=IP Security Agreement Ridge wSchedule A#page15.tif
source=IP Security Agreement Ridge wSchedule A#page16.tif
source=IP Security Agreement Ridge wSchedule A#page17.tif
source=IP Security Agreement Ridge wSchedule A#page18.tif
source=IP Security Agreement Ridge wSchedule A#page19.tif
source=IP Security Agreement Ridge wSchedule A#page20.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT ("Agreement") is made as of November 7, 2013 by RIDGE DIAGNOSTICS, INC., a Delaware corporation ("Pledgor"), in favor of VINDRAUGA CORPORATION, a California corporation ("Lender"), with reference to the facts set forth below:

A. Pledgor has obtained a loan ("Loan") from VINDRAUGA CORPORATION, a California corporation ("Lender"), and in connection therewith has executed and delivered a Promissory Note dated of even date herewith (the "Note") in favor of Lender. Except as otherwise provided in this Agreement, terms with initial capital letters herein shall have the same meanings as set forth in the Note and that certain Loan Agreement, dated of even date herewith (the "Loan Agreement").

B. As a condition to making the Loan, Lender requires that Pledgor grant a security interest in and to certain property to Lender for purposes of securing all of the obligations to be performed by Pledgor pursuant to the Loan Agreement. Pledgor hereby acknowledges and agrees that it will derive personal benefit by Lender making the loan to Pledgor pursuant to the Loan Documents (defined below).

C. To induce Lender to make the Loan, Pledgor is willing to grant a security interest in and to such property to Lender on the provisions and conditions hereinafter set forth.

NOW, THEREFORE to induce Lender to make the Loan and in consideration for the making of the Loan, Pledgor agrees as set forth below:

1. Definitions; Interpretation.

(a) Defined Terms. As used in this Agreement, the following terms shall have the following meanings:

"Business" shall mean the current business operations of Pledgor and all future business operations of Pledgor.

"Collateral" has the meaning set forth in Section 2.

"Copyright Collateral" has the meaning set forth in Section 2.

"Copyrights" has the meaning set forth in Section 2.

"Event of Default" has the meaning ascribed thereto in Section 7.

"Existing Interest Holders" means any of the Persons holding the Existing Interests.

"Existing Interests" means any interests in the Collateral or portions thereof existing on the date hereof in favor of any of the Persons as listed on Schedule "B" pursuant to the agreements referred to therein.

"Lender" shall have the meaning ascribed to such term in the introductory paragraph of this Agreement.

"Lien" means any pledge, security interest, assignment, charge or encumbrance, lien (statutory or other), or other preferential arrangement (including any agreement to give any security interest).

"Loan Agreement" shall have the meaning ascribed to such term in the introductory paragraph of this Agreement and shall include all modifications, amendments, renewals, replacements and extensions thereof.

"Loan Documents" shall mean the Loan Agreement and all other documents executed by Pledgor or any other party in connection with evidencing or securing the Loan.

"Material Adverse Effect" means a circumstance or event or any set of circumstances or events which has or could reasonably be expected to have any material adverse effect upon: (a) the condition, operations, assets, business or prospects of Pledgor; (b) Pledgor's ability to pay and perform the Obligations; (c) the value or priority of Lender's security interest in any Collateral; and/or (d) the practical realization of the benefits of Lender's rights and remedies under this Agreement and the other Loan Documents.

"Obligations" shall have the meaning ascribed to such term in Section 3 of this Agreement.

"Patent Collateral" has the meaning set forth in Section 2.

"Patents" has the meaning set forth in Section 2.

"Person" means an individual, corporation, partnership, limited liability company, joint venture, trust, unincorporated organization or any other entity.

"Pledgor Documents" means this Agreement together with any collateral assignments of licenses made by Pledgor in favor of Lender, any security agreements for licenses made by Pledgor in favor of Lender, and all other similar documents relating to licenses executed by Pledgor in connection with the Loan Documents.

"Pledgor" shall have the meaning ascribed to such term in the introductory paragraph of this Agreement.

"Proceeds" means whatever is receivable or received from or upon the sale, lease, license, sublicense, franchise, subfranchise, collection, use, exchange or other disposition, whether voluntary or involuntary, of any Collateral, including "proceeds" as defined at UCC Section 9-102 (whether in the form of goods, money, instruments, chattel paper,

documents, accounts, deposit accounts, investment property, insurance, general intangibles, rights to proceeds of written letters of credit or otherwise), all insurance proceeds and all proceeds of proceeds. Proceeds shall also include: (i) any and all accounts, chattel paper, instruments, license fees, franchise fees, management fees, distributorship fees, royalties, required or permissible product purchase payments, general intangibles, cash and other proceeds, payable to or for the account of Pledgor, from time to time in respect of any of the Collateral and/or Pledgor's Business; (ii) any and all proceeds of any insurance, indemnity, warranty or guaranty payable to or for the account of Pledgor from time to time with respect to any of the Collateral; (iii) any and all claims and payments (in any form whatsoever) made or due and payable to Pledgor from time to time in connection with any requisition, confiscation, condemnation, seizure or forfeiture of all or any part of the Collateral by any Person acting under color of governmental authority; and (iv) any and all other amounts from time to time paid or payable under or in connection with any of the Collateral or for or on account of any damage or injury to or conversion of any Collateral by any Person.

"PTO" means the United States Patent and Trademark Office and any successor thereto.

"Trade Secret Collateral" has the meaning set forth in Section 2.

"Trade Secrets" has the meaning set forth in Section 2.

"Trademark Collateral" has the meaning set forth in Section 2,

"Trademarks" has the meaning set forth in Section 2.

"UCC" means the Uniform Commercial Code as in effect from time to time in the State of California.

"United States" and "U.S." each mean the United States of America.

(b) Terms Defined in UCC. Where applicable and except as otherwise defined herein, terms used in this Agreement shall have the meanings assigned to them in the UCC.

(c) Interpretation. In this Agreement, except to the extent the context otherwise requires: (i) any reference to a Section or a Schedule is a reference to a section hereof, or a schedule hereto, respectively, and to a subsection or a clause is, unless otherwise stated, a reference to a subsection or a clause of the Section or subsection in which the reference appears; (ii) the words "hereof," "herein," "hereto," "hereunder" and the like mean and refer to this Agreement as a whole and not merely to the specific Section, subsection, paragraph or clause in which the respective word appears; (iii) the meaning of defined terms shall be equally applicable to both the singular and plural forms of the terms defined; (iv) the words "including," "includes" and "include" shall be deemed to be followed by the words "without limitation"; (v) references to agreements and other contractual instruments shall be deemed to include all subsequent amendments and other modifications thereto; (vi) references to statutes or regulations are to be construed as including all statutory and regulatory provisions consolidating, amending or

replacing the statute or regulation referred to; and (vii) any captions and headings are for convenience of reference only and shall not affect the construction of this Agreement.

2. Security Interest. To secure the Obligations (as defined in Section 3 below), Pledgor does hereby irrevocably pledge, assign and grant to Lender a security interest in all of Pledgor's worldwide right, title and interest in and to all of the following property, now adopted, used, registered, unregistered, owned or hereafter acquired or created (collectively, the "Collateral"):

(a) Trademark Collateral. (i) All common law, state, federal and internationally registered trademarks, service marks, trade names, corporate names, company names, business names, fictitious business names, product names, slogans, trade styles, trade dress, color marks and designs, logos, domain names, other source or business identifiers, designs and general intangibles of like nature, now existing or hereafter adopted or acquired in any way relating to the Business or otherwise, together with and including all licenses therefor held by Pledgor, and all registrations and recordings thereof, and all applications filed or to be filed in connection therewith, and all extensions and renewals thereof, including, without limitation any of the foregoing identified on Schedule "A" hereto (as the same may be amended, modified or supplemented from time to time), together with the goodwill of the Business symbolized by or associated with all of the foregoing (collectively, the "Trademarks"); (ii) all modifications, variations, derivative marks and names based upon the Trademarks used in Pledgor's Business now or in the future, and the goodwill of the Business associated with such names and marks or other Trademarks; (iii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the Trademarks, including license fees and royalties under license and other agreements; (iv) all claims, causes of action, damages and recoveries for past, present and future infringements or unauthorized use of any of the Trademarks and all rights arising therefrom and pertaining thereto; (v) all rights corresponding to the Trademarks throughout the world; (vi) all general intangibles (as defined in the UCC) and all intangible intellectual property or other similar property of Pledgor of any kind or nature, whether now owned or hereafter acquired or used, associated with or arising out of any of the Trademarks (including without limitation all license, distributorship and/or franchise agreements and rights under any Existing Interests) not otherwise described herein and all of the goodwill of Pledgor's Business symbolized by the Trademarks or associated therewith; (vii) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (viii) all Proceeds and products of any and all of the foregoing (all of the foregoing, collectively, the "Trademark Collateral").

(b) Trade Secret Collateral. (i) All trade secrets, confidential information, know-how and other intellectual property used in the Business of Pledgor now or in the future and all renewals, modifications, derivatives and improvements relating thereto (collectively, the "Trade Secrets"); (ii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the Trade Secrets, including license fees and royalties under license and other agreements; (iii) all claims, causes of action, damages and recoveries for past, present and future infringements or unauthorized use of any of the Trade Secrets and all rights arising therefrom and pertaining thereto; (iv) all rights corresponding to the Trade Secrets throughout the world; (v) all general intangibles (as defined in the UCC) and all intangible intellectual property or other similar property of Pledgor of any kind or nature, whether now owned or

hereafter acquired or developed, associated with or arising out of the Trade Secrets (including without limitation all license, distributorship and/or franchise agreements and rights under any Existing Interests) and not otherwise described herein; (vi) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (vii) all Proceeds and products of any and all of the foregoing (all of the foregoing, collectively, the "Trade Secret Collateral").

(c) Copyright Collateral. (i) All published and unpublished works of authorship that Pledgor owns or uses in its Business or will in the future adopt and so use (including all advertising and promotional materials, franchise agreements and franchise operation manuals) all original and derivative works of authorship and works protectable by copyright that are presently or in the future may be, owned, created, authored, acquired or used (pursuant to a license or otherwise) by Pledgor or by its employees, independent contractors, third parties or acquired by Pledgor, all of Pledgor's proprietary object code, source code, source data files and documentation in any way related to the Business and any modifications and derivative works related thereto, all copyright registrations and applications for copyright registration that previously have been or may hereafter be issued thereon or applied for in the U.S. or anywhere in the world, all registrations resulting from such copyright applications, and all renewals, modifications, extensions, derivative works and collective works thereof or related to any of the foregoing, throughout the world, together with all copyright licenses held by Pledgor, and all common law rights, copyrights, rights of authorship and moral rights related to any of the foregoing, including without limitation, any of the foregoing identified on Schedule "A" hereto (as the same may be amended, modified or supplemented from time to time) (collectively, the "Copyrights"); (ii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the foregoing, including license fees and royalties under license and other agreements; (iii) all claims, causes of action, damages and recoveries for past, present and future infringements or unauthorized use of any of the Copyrights and all rights arising therefrom and pertaining thereto; (iv) all rights corresponding to the Copyrights throughout the world; (v) all general intangibles (as defined in the UCC) and all intangible intellectual property or other similar property of Pledgor of any kind or nature, whether now owned or hereafter acquired or developed, associated with or arising out of any of the Copyrights (including without limitation all license, distributorship and/or franchise agreements and rights under any Existing Interests) and not otherwise described herein; (vi) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (vii) all Proceeds and products of any and all of the foregoing (all of the foregoing, collectively, the "Copyright Collateral").

(d) Patent Collateral. (i) All patents and patent applications (including, without limitation, the inventions, devices, specifications and improvements described and claims therein) filed in the U.S. or in any other country, owned, held or used by Pledgor in whole or in part, and all patent and invention disclosures related thereto, together with all reissuances, divisions, continuations, continuations-in-part, renewals, extensions, re-examinations, supplementary protection certificates, modifications, derivatives and improvements thereof and the inventions disclosed therein, and all new or separate patents that may be issued in connection with the foregoing, and all other inventions (whether patentable or unpatentable, whether or not reduced to practice or developed alone or jointly with others), and together with and including all patent licenses held by Pledgor, and all other rights, including the right to make, use, license, sell, exploit and otherwise transfer the inventions disclosed therein, including without limitation, any of the foregoing identified on Schedule "A" hereto (as the same may be amended, modified

or supplemented from time to time) (collectively the "Patents"); (ii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the Patents, including license fees and royalties under license and other agreements; (iii) all claims, causes of action, damages and recoveries for past, present and future infringements thereof or unauthorized use of any of the Patents and all rights arising therefrom and pertaining thereto; (iv) all rights corresponding to the Patents throughout the world; (v) all general intangibles (as defined in the UCC) and all intangible intellectual property or other similar property of Pledgor of any kind or nature, whether now owned or hereafter acquired or developed, associated with or arising out of any of the Patents (including without limitation all license, distributorship and/or franchise agreements and rights under any Existing Interests) and not otherwise described herein; (vi) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (vii) all products and Proceeds of any and all of the foregoing (all of the foregoing, collectively, the "Patent Collateral").

3. Obligations Secured. This Agreement and the security interest granted by this Agreement secure (in such order of priority as Lender may determine, in its sole discretion) the payment, performance, observance and satisfaction by Pledgor of all of its obligations under all of the following and all modifications, amendments, renewals, replacements and extensions of each of them (collectively, the "Obligations"): (a) the Loan Documents; (b) all obligations of Pledgor under the Pledgor Documents; (c) all other indebtedness and obligations of Pledgor to Lender whether currently existing or hereafter arising; (d) all amounts that Lender may advance or spend for the maintenance or preservation of the Collateral, and any other expenditures that Lender may make pursuant to the provisions of this Agreement or for the benefit of Pledgor; and (e) any of the foregoing that arises after the filing of a petition by or against Pledgor pursuant to the United States Bankruptcy Code, even if the Obligations do not accrue because of the automatic stay under Bankruptcy Code Section 362 or otherwise.

4. Further Assurances; Appointment of Lender As Attorney-In-Fact. Pledgor, at its expense, shall execute and deliver, or cause to be executed and delivered, to Lender any and all documents and instruments, in form and substance reasonably satisfactory to Lender, and take any and all action, which Lender may reasonably request from time to time, in order to evidence, protect, maintain, perfect or continue the security interest of Lender in the Collateral, to effectuate or enforce the rights granted to Lender hereunder, or to otherwise carry out the purposes and intent of this Agreement. Without limiting the foregoing, Pledgor authorizes Lender to file financing statements and such other instruments as may be necessary or desirable to perfect security interests created hereby in all states, counties and other jurisdictions as Lender may elect, without Pledgor's signature if permitted by law, describing the Collateral. Pledgor hereby irrevocably appoints Lender as its true and lawful attorney-in-fact with full power of substitution in the place and stead of Pledgor and in the name of Pledgor, Lender or otherwise, from time to time in Lender's discretion to do the following: (a) to sign or endorse the name of Pledgor on all or any of such documents or instruments and perform all other acts that Lender reasonably deems necessary or advisable in order to perfect or continue perfection, maintain the priority or enforceability of or provide notice of Lender's security interest in the Collateral; (b) to execute any and all other applications, documents and instruments and to perform any and all acts and things for and on behalf of Pledgor, which Lender may reasonably deem necessary or advisable to maintain, preserve and protect the Collateral and to accomplish the purposes of this Agreement, including (i) to defend, settle, adjust or institute any action, suit or proceeding with

respect to the Collateral, (ii) to assert or retain any rights under any license, distribution or franchise agreement for or with respect to any of the Collateral and (iii) to execute any and all applications, documents, papers and instruments for Lender to use the Collateral, to grant or issue any exclusive or non-exclusive license with respect to any Collateral, and to assign, convey or otherwise transfer title in or dispose of the Collateral; and (c) to take any other actions with respect to the Collateral, consistent with the terms of this Agreement, as Lender deems reasonably necessary or in the best interest of Lender. The power of attorney set forth in this Section 4 is coupled with an interest and is irrevocable so long as this Agreement shall be in effect. Pledgor hereby ratifies all that Lender shall lawfully do or cause to be done by virtue hereof.

5. Covenants. Pledgor covenants and agrees that, to the best of its ability, as long as this Agreement shall be in effect:

(a) Pledgor shall use commercially reasonable efforts to (i) actively police and defend the Collateral, file and prosecute lawsuits, interference, opposition and cancellation proceedings, and take such other actions as necessary to protect the strength of and rights in the Collateral, (ii) protect, defend and maintain the validity and enforceability of the Collateral, (iii) ascertain or discover any infringements or violations of the Collateral and promptly advise Lender in writing of any infringements or violations detected, and (iv) not allow any Collateral to be abandoned, forfeited or dedicated to the public without the consent of Lender which shall not be unreasonably withheld; provided, however, Pledgor may abandon and/or forfeit any application, filing and/or registration in any foreign (non-United States) jurisdiction but only after Pledgor has reasonably determined that such abandonment and/or forfeiture will not result in a Material Adverse Effect. Lender shall have the right, but not the obligation, to take, at Pledgor's sole expense, in its own name or in Pledgor's name or in the names of the parties jointly any actions that Pledgor is required to take under this section or other provisions of this Agreement, but which Pledgor fails to take. Pledgor shall prosecute any infringement or violation of the Collateral to protect the Collateral as required by this Agreement, giving due consideration to value, importance, cost and opinion of counsel as to such action. If Pledgor decides not to prosecute an infringement or violation of the Collateral, Pledgor shall promptly notify Lender in writing explaining the facts and reasons why Pledgor has decided not to pursue such infringement or violation. If Lender reasonably determines that such infringement or violation must be prosecuted in order to protect Lender's interest in the Collateral, Lender shall so notify Pledgor in writing and Pledgor shall thereafter promptly prosecute such infringement or violation at Pledgor's expense;

(b) Pledgor shall promptly, upon its becoming aware thereof, notify Lender in writing of the existence or receipt of (i) any claim, dispute, lawsuit, arbitration, opposition, cancellation or interference proceeding, or other proceeding that in any way involves or relates to any of the Collateral, (ii) any adverse determination in or with respect to any of the pending or future applications for registration or registrations of any of the Collateral, and/or (iii) any adverse determination in or with respect to any lawsuits or other proceedings regarding the Collateral or regarding Pledgor's claim of ownership in or right to use any of the Collateral; Pledgor shall promptly provide to Lender any information with respect thereto required from time to time by Lender;

(c) Pledgor shall renew, preserve and maintain all Patents, Trademarks, Copyrights, Trade Secrets and other Collateral in a reasonable and timely manner, including without limitation filing all required affidavits and other documents and paying all necessary maintenance and other fees; provided, however, Pledgor may forego renewal, preservation and/or maintenance of any of the foregoing in any foreign (non-United States) jurisdiction but only after Pledgor has reasonably determined that such abandonment and/or forfeiture will not result in a Material Adverse Effect.

(d) Pledgor shall not sell, pledge, encumber, lien, hypothecate, assign, license, franchise, distribute or otherwise dispose of any rights in any of the Patents, Trademarks, Copyrights, Trade Secrets or other Collateral to any third party, in the U.S. or internationally, without the express, written consent of Lender, which consent shall not be unreasonably withheld by Lender;

(e) Lender shall have no obligation or responsibility to preserve, protect or defend the Collateral and Pledgor shall at its own expense protect, defend and maintain the same as required by this Agreement or specifically by Lender from time to time in its sole discretion;

(f) Pledgor shall use commercially reasonable efforts to prosecute diligently any Patent, Copyright, Trademark or other intellectual property application pending as of the date hereof or hereafter. Pledgor shall notify Lender in writing of any such applications filed and/or registrations received for any of the Patents, Trademarks, Copyrights or other Collateral, and the parties shall amend this Agreement, any assignments, UCC-1 Financing Statements, Memorandum of Security Agreement or other document to reflect such applications and registrations. Pledgor shall diligently file and prosecute applications for registration for all major variations and improvements to the Trademarks, Copyrights and Patents, including derivative and collective marks and works upon their adoption and use;

(g) Pledgor shall employ notices and proprietary markings in compliance with applicable legal requirements or as permitted to maximize the protection and enforcement of the Collateral;

(h) If Pledgor fails to comply with any of its covenants or agreements herein, Lender may do so in Pledgor's name or in Lender's name, at Pledgor's expense, and Pledgor shall reimburse Lender for all expenses, including reasonable attorney's fees and costs, incurred by Lender in protecting, defending and maintaining the Collateral;

(i) Pledgor shall not enter into any agreement (for example, a license agreement, distribution agreement, joint development agreement, franchise agreement or work for hire agreement) that would allow actual or potential Collateral to become all or partly owned by any other Person, or that is inconsistent with Pledgor's obligations under this Agreement, without Lender's prior written consent;

(j) Pledgor shall not take any action, or permit any action to be taken by others subject to its control, including licensees, joint venture partners, franchisees, vendors, or joint developers, or fail to take any action, if doing so or not doing so would impair the title to, or validity or enforceability of the Collateral and/or of Lender's interest in the Collateral;

(k) Pledgor shall permit Lender, at any reasonable time, upon reasonable frequency, and upon reasonable prior written notice, to inspect Pledgor's premises and to examine Pledgor's books, records, operations, and use and protection of the Patents, Trademarks, Copyrights, Trade Secrets and other Collateral, and permit Lender to make and retain copies of any of the Collateral and of such books and records in order to protect its interest in the Collateral;

(l) Pledgor shall, promptly after executing this Agreement, to the extent not previously provided to Lender, provide to Lender a copy of the written agreements between Pledgor and the Existing Interest Holders;

(m) Pledgor shall pay when due all taxes and assessments against the Collateral and all claims and demands arising from Pledgor's ownership or use of the Collateral, and will not cause or permit any Lien to be imposed on or to exist against the Collateral;

(n) Pledgor shall make no change to its organization status or existence, state of incorporation, corporate identification number, or name, nor merge into or consolidate with any other Person, in each case without providing Lender at least thirty (30) days' prior written notice; and

(o) Pledgor shall, with respect to Collateral consisting of rights in or under agreements, contracts, accounts, instruments, leases, permits, licenses, franchises, and the like, now existing or hereafter acquired or entered into, including any license agreements made by Pledgor (collectively, "Third Party Agreements") do the following:

(i) except with respect to Third Party Agreements of inconsequential value, the breach or loss of which could have no material adverse effect on Pledgor, the Business or any of the remaining Collateral, Pledgor will, at its sole cost and expense (a) perform and satisfy every obligation and condition of the Third Party Agreements to be performed or satisfied by Pledgor; (b) give prompt notice to Lender of any notice of default given or received by Pledgor under any Third Party Agreements, together with a copy of any such notice of default; (c) enforce, short of termination, the performance and satisfaction of every obligation and condition of the Third Party Agreements to be performed or satisfied by the other parties to the Third Party Agreements; and (d) appear in and defend any action arising from or relating to the Third Party Agreements or the obligations of any party under any Third Party Agreement;

(ii) except with respect to Third Party Agreements of inconsequential value, the breach or loss of which could have no material adverse effect on Pledgor, the Business or any of the remaining Collateral, Pledgor will not, without Lender's prior written consent, take any action to (a) terminate or amend any Third Party Agreements; (b) waive or release the parties to any Third Party Agreements from any obligation or condition to be performed or satisfied by such parties; (c) assign, transfer, pledge or otherwise encumber any of its rights in any Third Party Agreements, absolutely or for security; or (d) revoke or countermand, or attempt or purport to revoke or countermand, the irrevocable authorizations and instructions set forth in Subsection (iii) below. Any such purported action by Pledgor without Lender's prior written consent will be void and will constitute a default under this Agreement;

(iii) Pledgor hereby irrevocably authorizes and instructs every present and future party under every Third Party Agreement, upon demand by Lender, to pay and perform all of such party's obligations directly and only to Lender, to recognize and accept Lender as the holder of all of Pledgor's rights and benefits under the Third Party Agreement for all purposes, and to accept any payment or performance by Lender of Pledgor's obligations under the Third Party Agreement that Lender may elect to tender. No such party shall have any duty to investigate the validity or accuracy of any such demand by Lender. Each such party shall be relieved of any liability to Pledgor for payment or performance under a Third Party Agreement to the extent that such party has paid or performed to Lender, pursuant to demand of Lender, even if it is later determined that Lender's demand for payment or performance was invalid. Lender shall have the right at any time to enforce Pledgor's rights against every present and future party under every Third Party Agreement (including without limitation the account debtors and obligors); and

(iv) Lender is not obligated to perform any obligations of Pledgor under any Third Party Agreement unless Lender so elects, and Pledgor shall remain liable under every Third Party Agreement to the same extent as if this Agreement had not been executed. The exercise by Lender of any rights and remedies under this Agreement shall not release Pledgor from any of its duties or obligations under any Third Party Agreement.

6. Representations and Warranties. Pledgor represents, warrants and covenants, to the best of its knowledge, that now and in the future during the pendency of this Agreement and until the Obligations are satisfied in full as follows:

(a) Schedule "A" sets forth a true, correct and complete list of all of the existing Trademarks, Copyrights and Patents that are registered or for which any application for registration has been filed with the PTO or any corresponding or similar office of any other jurisdiction and that are owned and used by Pledgor, in whole or in part;

(b) Schedule "B" which sets forth the Existing Interests and Existing Interest Holders, sets forth a true, correct and complete list of all Existing Interest Holders to whom Pledgor has pledged, licensed, franchised or distributed any of the Collateral and all of the agreements giving rise to the Existing Interests;

(c) The Collateral and all portions thereof is subsisting, has not been adjudged invalid or unenforceable in whole or in part, is not currently being challenged in any way, and there are no pending or threatened claims, litigation, proceedings or other investigations regarding any of the Collateral. Except as otherwise disclosed to Lender in writing prior to the date of this Agreement, none of the Collateral has lapsed or expired or been abandoned or allowed to fall into the public domain;

(d) All maintenance, renewal and other fees required to be paid on account of any Collateral have been timely paid for maintaining such Collateral in force, and all affidavits of use required to be filed with respect to any Trademarks have been timely filed to maintain such Trademarks in force;

(e) Pledgor owns the entire worldwide right, title and interest in and to the Collateral and each portion thereof free and clear of any Liens and rights of others, except for the Liens and rights granted by Pledgor pursuant to this Agreement and the Existing Interests of the Existing Interest Holders (provided Lender's security interest in the Collateral is senior in priority to the Existing Interests); and each such license, franchise or distribution agreement giving rise to the Existing Interests is in full force and effect, and other than parties to such license, franchise or distribution agreements, to Pledgor's knowledge, no other Person has any rights to or in any of the Collateral;

(f) Pledgor has the unqualified right, power and authority to pledge and grant to Lender a first priority security interest in all of the Collateral, and execute, deliver and perform its obligations in accordance with the terms of this Agreement, without the consent or approval of any other Person except as already obtained; this Agreement has been fully authorized, executed and delivered, and constitutes a legal, valid and binding agreement of Pledgor enforceable in accordance with its terms; and the execution, delivery and performance by Pledgor of this Agreement do not violate any provision of law or the articles of incorporation or bylaws of Pledgor or result in a breach of or constitute a default under any contract, obligation, indenture or other instrument to which Pledgor is a party or by which Pledgor may be bound;

(g) Pledgor has continually used in commerce all Trademarks once use of such has commenced;

(h) Pledgor has in place a commercially reasonable system to protect its Trade Secrets. Pledgor has taken and will continue to take all commercially reasonable steps to protect the confidentiality of all Trade Secrets;

(i) Neither Pledgor nor any of the Existing Interest Holders are in breach or default of any of the Third Party Agreements and no event has occurred which with notice or lapse of time would constitute a breach or default, or permit the termination or modification of any of the Third Party Agreements;

(j) Pledgor has not transferred, pledged or otherwise encumbered any of its rights or interests in or under any of the Third Party Agreements;

(k) Pledgor, the Collateral, and products sold or services rendered by Pledgor, and/or any processes used by Pledgor in its Business do not infringe or violate any third party's intellectual property rights, and no claim has been made that the use of any of the Collateral or any products or services incorporating any of the Collateral constitutes an infringement or violation of any third party's intellectual property rights. Pledgor has not engaged in any conduct that would constitute unfair competition, unfair trade practices, defamation or otherwise would conflict with another Person's intellectual property rights or other rights. To Pledgor's knowledge, no third parties are infringing upon or violating any of the rights in any of the Collateral;

(l) Schedule "A" sets forth a true, accurate and complete list of all material technologies and proprietary rights of Pledgor that are necessary to operate Pledgor's Business;

(m) Pledgor has not agreed with any other Person not to sue or otherwise enforce any legal or equitable rights regarding the Collateral; and

(n) Pledgor shall undertake all reasonable measures to cause its employees, agents and independent contractors to assign to Pledgor all rights in and to any Collateral in which Pledgor has or may subsequently acquire any right or interest.

7. Event of Default. It shall be an "Event of Default" hereunder if Pledgor shall fail to perform or comply with any of the provisions of this Agreement, or if any representation or warranty made herein shall be false or misleading in any material respect, or if an "Event of Default" shall exist under and as defined in any one or more of the Loan Documents. Pledgor expressly acknowledges and agrees that this Section 7 is intended to and does hereby cross-default this Agreement with the Pledgor's obligations under the Loan Documents, such that the occurrence of any Event of Default under any one or more of the Loan Documents shall constitute an immediate Event of Default hereunder. Lender shall provide Pledgor a written notice of an Event of Default. Notwithstanding anything to the contrary in this paragraph, it shall not be an "Event of Default" if Pledgor shall rectify the default to the satisfaction of Lender within five (5) business days after receipt of such notice for an Event of Default that involves a monetary Event of Default and within ten (10) business days after receipt of such notice for any other (non-monetary) Event of Default; provided, however, the foregoing shall not be construed to create an additional cure period for an Event of Default in addition to the cure rights set forth in the other Loan Documents.

8. Remedies. From and after the occurrence of an Event of Default, for so long as such Event of Default remains uncured, Lender shall have all rights and remedies available to it under this Agreement, under the Loan Documents and under applicable law (which rights and remedies are cumulative). Pledgor agrees that such rights and remedies include the right of Lender as a secured party to sell or otherwise dispose of the Collateral after default, pursuant to the UCC. Pledgor agrees that, in addition to its other rights, Lender shall at all times have such worldwide, royalty-free, exclusive, transferable, licenses (including the right to sublicense) for any Collateral that is reasonably necessary to permit the exercise of any of Lender's rights or remedies hereunder, including upon or after the occurrence of an Event of Default with respect to any assets of Pledgor in which Lender has a security interest, including Lender's rights to sell inventory, tooling, equipment or packaging which is owned or acquired by Pledgor (or its successor, assignee or trustee in bankruptcy). In addition to and without limiting any of the foregoing, upon the occurrence of an Event of Default, Lender shall have the right, but not the obligation, to bring suit or to take such other action as Lender deems necessary or advisable, in the name of Pledgor or Lender, to enforce its rights under this Agreement or to enforce or protect any of the Collateral, in which event Pledgor shall, at the request of Lender, do any and all lawful acts and execute any and all documents required by Lender in aid of such enforcement. Pledgor acknowledges and agrees that Lender may execute and acknowledge any and all such documents pursuant to the power of attorney granted to Lender hereunder but shall have no fiduciary duties to Pledgor thereunder to the maximum extent permitted by applicable law.

9. Indemnity. Pledgor shall indemnify, defend and hold Lender and its officers, directors, employees, agents, and affiliates (collectively, the "Indemnitees" and individually an "Indemnatee") harmless from and against any and all other liabilities, obligations, losses,

damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatever (including, without limitation, the reasonable fees and disbursements of counsel for such Indemnites in connection with any investigative, administrative or judicial proceeding commenced or threatened, whether or not such Indemnites are designated parties thereto) that may be imposed on, incurred by, or asserted against the Indemnites, in any manner relating to or arising out of the Agreement or out of any undertaking or proceeding related to any of the transactions contemplated hereby or any act, omission, event or transaction related or attendant thereto, including amounts paid in settlement, court costs, and the fees and expenses of counsel (collectively, the "Indemnified Liabilities"); *provided, however*, that Pledgor shall have no obligation to an Indemnitee hereunder with respect to Indemnified Liabilities arising from the negligence or willful misconduct of that Indemnitee.

10. Miscellaneous.

(a) Termination. The security interest in the Collateral granted hereunder shall remain in full force and effect until the Obligations are satisfied in full and the Loan Documents and any commitment to extend any financial accommodation thereunder have been terminated. At such time, Lender shall, within five (5) business days, execute and deliver to Pledgor, or to a third party upon Pledgor's instructions, for filing with the appropriate government entity in the U.S. or elsewhere and in each office in which any financing statement pertaining to the security interest granted hereby may have been filed: (i) documentation in accordance with the rules and regulations of such office, (ii) termination statements under the UCC, and (iii) any other documentation reasonably requested by Pledgor, all as may be necessary to release Lender's interest in the Collateral.

(b) Governing Law; Venue; Jury Waiver. If there is a lawsuit or other proceeding, Pledgor agrees upon Lender's request to submit to the jurisdiction of the courts of San Diego County, California. To the extent permitted under applicable laws, Lender and Pledgor hereby waive the right to any jury trial in any action, proceeding or counterclaim brought by Lender or Pledgor against the other, and each waive any right to object to or contest the venue or jurisdiction selected by Lender. This Agreement will be governed by, construed and enforced in accordance with federal law and the laws of the State of California.

(c) Entire Agreement. This Agreement and that certain Security Agreement (Blanket) dated as of the date hereof, constitutes the entire agreement between the parties regarding the subject matter hereof, and supersedes all prior or contemporaneous understandings or agreements, whether oral or written regarding the subject matter hereof. No alteration of or amendment to this Agreement shall be effective unless given in writing and signed by the party or parties sought to be charged or bound by the alteration or amendment.

(d) Notice. All notices, requests, demands and other communications required or permitted to be given hereunder shall be in writing and shall be given personally, sent by facsimile transmission, electronic mail, prepaid air courier or certified, registered or express mail, postage prepaid. Any such notice shall be deemed to have been given or made for all purposes: (a) in any event, upon actual receipt by the recipient; (b) upon confirmation receipt (or oral confirmation) that the communication was successfully sent to the recipient if sent by facsimile or other electronic communication; (c) one day after being sent, when sent by

professional overnight courier service; or (d) three (3) business days after posting when sent by registered or certified mail. All notices, communications and/or payments should be addressed to the party for whom intended, as follows:

To Lender: VINDRAUGA CORPORATION
1565 Hotel Circle South, Suite 310
San Diego, California 92108
Attn: James R. Wade
Facsimile: (619) 220-8112

To Pledgor: RIDGE DIAGNOSTICS, INC.
4225 Executive Square, Suite 600
La Jolla, California 92037
Attn: Lonna J. Williams
Facsimile: () -

(e) Costs and Expenses. Pledgor agrees to pay upon demand all of Lender's costs and expenses, including Lender's attorneys' fees and Lender's legal expenses, incurred in connection with the preparation, execution, enforcement, modification and collection of this Agreement. Lender may hire or pay someone else to help collect the Obligations and to enforce this Agreement, and Pledgor shall pay the costs and expenses of such collection and enforcement. Costs and expenses include Lender's attorneys' fees and Lender's legal expenses whether or not there is a lawsuit, including attorneys' fees and legal expenses for bankruptcy proceedings (including efforts to modify or vacate any automatic stay or injunction), appeals, and any anticipated post-judgment collection services. Pledgor also shall pay all court costs and such additional fees as may be directed by the court.

(f) Severability. If a court of competent jurisdiction finds any provision of this Agreement to be illegal, invalid, or unenforceable as to any circumstance, that finding shall not make the offending provision illegal, invalid, or unenforceable as to any other circumstance. If feasible, the offending provision shall be considered modified so that it becomes legal, valid and enforceable. If the offending provision cannot be so modified, it shall be considered deleted from this Agreement. Unless otherwise required by law, the illegality, invalidity, or enforceability of any provision of this Agreement shall not affect the legality, validity or enforceability of any other provision of this Agreement.

(g) Successors and Assigns. All covenants and agreements contained by or on behalf of Pledgor shall bind Pledgor's successors and assigns and shall inure to the benefit of Lender and its successors and assigns. Pledgor shall not, however, have the right to assign Pledgor's rights under this Agreement or any interest therein, without the prior written consent of Lender.

(h) Survival. Pledgor understands and agrees that in making the Loan and other financial accommodations set forth in the Loan Documents, Lender is relying on all representations, warranties, and covenants made by Pledgor in this Agreement or in any certificate or other instrument delivered by Pledgor to Lender under this Agreement. Pledgor further agrees that regardless of any investigation made by Lender, all such representations,

warranties and covenants will survive the making of the Loan and other financial accommodations set forth in the Loan Documents, shall be continuing in nature, and shall remain in full force and effect until such time as all Obligations shall be paid and satisfied in full, or until this Agreement shall be terminated in the manner provided above, whichever is the last to occur.

(i) Time is of the Essence. Time is of the essence in the performance of this Agreement.

(j) Waiver. Lender shall not be deemed to have waived any right under this Agreement unless such waiver is given in writing and signed by Lender. No delay or omission on the part of Lender in exercising any right shall operate as a waiver of such right or any other right. A waiver by Lender of a provision of this Agreement shall not prejudice or constitute a waiver of Lender's right otherwise to demand strict compliance with that provision or any other provision of this Agreement. No prior waiver by Lender nor any course of dealing between Lender and Pledgor shall constitute a waiver of any of Lender's rights or Pledgor's obligations as to any future transactions. Whenever the consent of Lender is required under this Agreement, the granting of such consent by Lender in any instance shall not constitute continuing consent in subsequent instances where such consent is required and in all cases such consent may be granted or withheld in the sole discretion of Lender.

(k) Counterparts. This Agreement may be executed in any number of counterparts and by different parties hereto and separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute but one and the same agreement.

* * * * *

IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first written above.

PLEDGOR:

RIDGE DIAGNOSTICS, INC.,
a Delaware corporation

By: Anna J. Williams
Name: Anna J. Williams
Its: CEO

TRADEMARK

REEL: 006850 FRAME: 0896

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

CIVIL CODE § 1189

State of California


County of San Diego

On 11/6/2013

before me, C.M. Parenteau, Notary Public

personally appeared

LONNA JEAN WILLIAMS



who proved to me on the basis of satisfactory evidence to be the person~~(s)~~ whose name~~(s)~~ is/~~are~~ subscribed to the within instrument and acknowledged to me that ~~he~~/she/~~they~~ executed the same in his/~~her~~/their authorized capacity~~(ies)~~, and that by his/~~her~~/their signature~~(s)~~ on the instrument the person~~(s)~~, or the entity upon behalf of which the person~~(s)~~ acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature:

C.M. Parenteau

Place Notary Seal Above

Signature of Notary Public

OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

Description of Attached Document

Title or Type of Document: IP Security Agreement for Ridge

Document Date:

Number of Pages:

Signer(s) Other Than Named Above:

Capacity(ies) Claimed by Signer(s)

Signer's Name: Lonna Jean Williams

Signer's Name:

☒ Corporate Officer — Title(s): CEO

☐ Corporate Officer — Title(s):

☐ Individual

☐ Individual

☐ Partner — ☐ Limited ☐ General

☐ Partner — ☐ Limited ☐ General

☐ Attorney in Fact

☐ Attorney in Fact

☐ Trustee

☐ Trustee

☐ Guardian or Conservator

☐ Guardian or Conservator

☐ Other:

☐ Other:

Signer Is Representing:

Ridge Diagnostics, Inc.

Signer Is Representing:

Schedule A to the Intellectual Property Security Agreement

Ridge Diagnostics, Inc
Intellectual Property Status List
As at 4 Oct 2013

F&R Ref.	Country	Serial No.	Filing Date	Pub. No.	Pub. Date	Patent No.	Issue Date	Status
Molecule Interaction Measurement Chip and System								
20436-0004P01	US	60/746,824	9-Dec-2005	-	-	-	-	Expired (converted to PCT)
20436-0004US1	US	12/305,950	19-Dec-2008	2010-0144052	10-Dec-2010	-	-	Pending
20436-0004WO1	WIPO	PCT/US2006/047244	11-Dec-2006	WO 2007/087819	14-Jun-2007	-	-	Expired (national phase)
Molecular Interaction Detection Chip and Fabrication Process								
20436-0005P01	US	60/784,322	21-Mar-2006	-	-	-	-	Expired (converted to PCT (0004WO1))
Precision Molecule Interaction Measurement System and Method								
20436-0006P01	US	60/796,585	1-May-2006	-	-	-	-	Expired (converted to PCT (0004WO1))
Quantitative Diagnostic Methods Using Multiple Parameters								
20436-0007001	US	11/850,550	5-Sep-2007	-	-	8,158,374	17-Apr-2012	Issued
20436-0007002	US	13/446,382	13-Apr-2012	2012-0289422	15-Nov-2012	8,450,877	28-May-2013	Issued
20436-0007003	US	13/903,346	28-May-2013	-	-	-	-	Pending
20436-0007P01	US	60/824,471	5-Sep-2006	-	-	-	-	Expired (converted to utility)
Diagnostics with multiple parameters -algorithm and methods								
20436-0008P01	US	60/910,217	5-Apr-2007	-	-	-	-	Expired (converted to utility (0007001))
Diagnostics with multiple parameters -algorithm and methods								
20436-0009P01	US	61/033,726	4-Mar-2008	-	-	-	-	Expired (converted to PCT)
20436-0009WO1	WIPO	PCT/US2009/036084	4-Mar-2009	WO 2009/111595	11-Sep-2009	-	-	Expired (national phase)
20436-0009CA1	Canada	2717763	4-Mar-2009	-	-	-	-	Pending
20436-0009CN1	China	200980115931.3	4-Mar-2009	CN10203755A	27-Apr-2011	-	-	Pending
20436-0009EP1	Europe	9717234	4-Mar-2009	2329260	8-Jun-2011	-	-	Pending
20436-0009JP1	Japan	2010-549663	4-Mar-2009	2011-518318	23-Jun-2011	-	-	Pending
20436-0009US1	US	12/921,349	4-Mar-2009	2011-0245092	6-Oct-2011	-	-	Pending
Combinations of Selected Biomarkers for Diagnosing Depression Disorders								
20436-0010P01	US	61/033,721	4-Mar-2008	-	-	-	-	Expired (converted to PCT (0009WO1))
Monitoring Depression Disorders Based on Hypothalamic-Pituitary-Adrenal (HPA) Axis Biomarkers								
20436-0011P01	US	61/033,731	4-Mar-2008	-	-	-	-	Expired (converted to PCT (0009WO1))
Inflammatory Biomarkers for Monitoring Depressive Disorders								
20436-0012P01	US	61/036,013	12-Mar-2008	-	-	-	-	Expired (converted to PCT)
20436-0012WO1	WIPO	PCT/US2009/036833	11-Mar-2009	WO 2009/114627	17-Sep-2009	-	-	Expired (national phase)
20436-0012CA1	Canada	2718273	11-Mar-2009	-	-	-	-	Pending
20436-0012CN1	China	200980116135.1	11-Mar-2009	CN 102016907A	13-Apr-2011	-	-	Pending
20436-0012EP1	Europe	9718958.3	11-Mar-2009	2272044	12-Jan-2011	-	-	Pending
20436-0012HK1	Hong Kong	11107199.1	12-Jul-2011	1153282	23-Mar-2012	-	-	Pending
20436-0012JP1	Japan	2010-550839	11-Mar-2009	2011-520095	14-Jul-2011	-	-	Pending
20436-0012US1	US	12/922,365	11-Mar-2009	2011-0269633	3-Nov-2011	-	-	Pending
Human Biomarker Hypermapping for Depressive Disorders								
20436-0013P01	US	61/105,641	15-Oct-2008	-	-	-	-	Expired (converted to PCT and utility)
20436-0013001	US	12/579,733	15-Oct-2009	2010-0100333	22-Apr-2010	-	-	Pending
20436-0013WO1	WIPO	PCT/US2009/060895	15-Oct-2009	WO 2007/036475	15-Mar-2007	-	-	Expired (national phase)
20436-0013CA1	Canada	2748736	15-Oct-2009	-	-	-	-	Pending
20436-0013CN1	China	200980147037.4	15-Oct-2009	CN 102257157A	23-Nov-2011	-	-	Pending

TRADEMARK

REEL: 006850 FRAME: 0880

20436-0013EP1	Europe	9821274.9	15-Oct-2009	2337866	29-Jun-2011	-	-	Pending
20436-0013HK1	Hong Kong	12105066.4	15-Oct-2009	1164379	21-Sep-2012	-	-	Pending
20436-0013JP1	Japan	2011-0532262	15-Oct-2009	2012-506053	8-Mar-2012	-	-	Pending
Combinations of Metabolic Syndrome and HPA Axis Biomarkers for Monitoring Major Depressive Disorder								
20436-0014P01	US	61/115,710	18-Nov-2008	-	-	-	-	Expired (converted to PCT and utility)
20436-0014001	US	12/620,831	18-Nov-2009	2010-0136700	3-Jun-2010	8,440,418	14-May-2013	Issued
20436-0014002	US	13/892,714	13-May-2013	-	-	-	-	Pending
20436-0014WO1	WIPO	PCT/US2009/064967	18-Nov-2009	WO 2010/059709	27-May-2010	-	-	Expired (national phase)
20436-0014CA1	Canada	2744151	18-Nov-2009	-	-	-	-	Pending
20436-0014CN1	China	200980153799.5	18-Nov-2009	CN 102301234A	28-Dec-2011	-	-	Pending
20436-0014EP1	Europe	9828159.5	18-Nov-2009	2356453	17-Aug-2011	-	-	Pending
20436-0014HK1	Hong Kong	12106344.8	18-Nov-2009	1165554	5-Oct-2012	-	-	Pending
20436-0014JP1	Japan	2011-537577	18-Nov-2009	2012-509480	19-Apr-2012	-	-	Pending
Biomarker Panels for Stratifying and Monitoring Major Depressive Disorder								
20436-0015P01	US	61/298,443	26-Jan-2010	-	-	-	-	Expired (converted to PCT and utility)
20436-0015001	US	13/014,413	26-Jan-2011	2011-0213219	1-Sep-2011	-	-	Pending
20436-0015WO1	WIPO	PCT/US2011/022573	26-Jan-2011	WO 2011/094308	4-Aug-2011	-	-	Expired (national phase)
20436-0015CA1	Canada	2788315	26-Jan-2011	-	-	-	-	Pending
20436-0015CN1	China	201180011737.8	26-Jan-2011	CN 102584428A	16-Jan-2013	-	-	Pending
20436-0015EP1	Europe	11737575.8	26-Jan-2011	2529222	5-Dec-2012	-	-	Pending
20436-0015JP1	Japan	2012-551263	26-Jan-2011	2013-518287	20-May-2013	-	-	Pending
Biomarkers for Monitoring Treatment of Neuropsychiatric Diseases								
20436-0016P01	US	61/165,662	1-Apr-2009	-	-	-	-	Expired (converted to PCT and utility)
20436-0016001	US	12/753,022	1-Apr-2010	2010-0280760	4-Nov-2010	-	-	Pending
20436-0016WO1	WIPO	PCT/US2010/029720	1-Apr-2010	WO 2010/0115061	7-Oct-2010	-	-	Expired (national phase)
20436-0016CA1	Canada	2757518	1-Apr-2010	-	-	-	-	Pending
20436-0016CN1	China	201080022306.7	1-Apr-2010	CN 102483398A	30-May-2012	-	-	Pending
20436-0016EP1	Europe	10759446.7	1-Apr-2010	2414824	8-Feb-2012	-	-	Pending
20436-0016HK1	Hong Kong	12112408.7	1-Apr-2010	1171807	5-Apr-2013	-	-	Pending
20436-0016JP1	Japan	2012-503731	1-Apr-2010	2012-522995	27-Sep-2012	-	-	Pending
Biomarkers for Monitoring Treatment of Neuropsychiatric Diseases								
20436-0017P01	US	61/166,985	6-Apr-2009	-	-	-	-	Expired (converted to PCT and utility)
20436-0017001	US	12/754,770	6-Apr-2010	2010-0280562	4-Nov-2010	-	-	Pending
20436-0017WO1	WIPO	PCT/US2010/030104	6-Apr-2010	WO 2010/118035	14-Oct-2010	-	-	Expired (national phase)
20436-0017CA1	Canada	2757659	6-Apr-2010	-	-	-	-	Pending
20436-0017CN1	China	2010800252866.8	6-Apr-2010	CN 102460153A	16-May-2012	-	-	Pending
20436-0017EP1	Europe	10762304.3	6-Apr-2010	2417446	18-Feb-2012	-	-	Pending
20436-0017NK	Hong Kong	12111712.0	6-Apr-2010	1171081	15-Mar-2013	-	-	Pending
20436-0017JP1	Japan	2012-504792	6-Apr-2010	2012-523009	27-Sep-2012	-	-	Pending
Human Biomarker Test for Major Depressive Disorder								
20436-0018P01	US	61/796,910	15-Mar-2013	-	-	-	-	Pending
Biomarkers for Monitoring Treatment of Neuropsychiatric Diseases								
20436-0020P01	US	61/420,141	6-Dec-2010	-	-	-	-	Expired (converted to PCT and utility)
20436-0020001	US	13/312,553	6-Dec-2011	2012-0176118	7/12/2012	-	-	Pending
20436-0020WO1	WIPO	PCT/US2011/063522	6-Dec-2011	-	-	-	-	Expired (national phase)
20436-0020CA1	Canada	2820616	6-Dec-2011	-	-	-	-	Pending
20436-0020CN1	China	201180066505.2	6-Dec-2011	-	-	-	-	Pending
20436-0020EP1	Europe	11846638.2	6-Dec-2011	-	-	-	-	Pending
20436-0020JP1	Japan	unknown	6-Dec-2011	-	-	-	-	Pending
Trademarks								
Serial Number	Reg. Number	Word Mark	Check Status	Live/Dead	Registration Date			
85264705	4117318	RIDGE DIAGNOSTICS	TSDR	LIVE	3/27/2012			
85264659	4117317	RIDGE DIAGNOSTICS	TSDR	LIVE	3/27/2012			

SCHEDULE "B"

List of Existing Interest Holders, Existing Interests and Third Party Agreements

TRADEMARK

Exhibit 3

UCC FINANCING STATEMENT

FOLLOW INSTRUCTIONS (front and back) CAREFULLY

A. NAME & PHONE OF CONTACT AT FILER [optional]

Phone: (619) 685-3177 Fax: (619) 702-6857

B. SEND ACKNOWLEDGEMENT TO: (Name and Address)

Seitzer Caplan McMahon Vitek
750 B Street, Suite 2100
San Diego, California 92101
Attn: Joseph P. Martinez, Esq.
Facsimile: (619) 702-6857

DELAWARE DEPARTMENT OF STATE
U.C.C. FILING SECTION
FILED 05:18 PM 11/08/2013
INITIAL FILING # 2013 4419884

SRV: 131289411

THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY

1. DEBTOR'S EXACT FULL LEGAL NAME - insert only one debtor name (1a or 1b) - do not abbreviate or combine names

1a. ORGANIZATION'S NAME					
RIDGE DIAGNOSTICS, INC., a Delaware corporation					
OR	1b. INDIVIDUAL'S LAST NAME		FIRST NAME	MIDDLE NAME	SUFFIX
1c. MAILING ADDRESS		CITY	STATE	POSTAL CODE	COUNTRY
4225 Executive Square, Suite 600		La Jolla	CA	92037	
ADD'L INFO RE ORGANIZATION DEBTOR		1a. TYPE OF ORGANIZATION	1f. JURISDICTION OF ORGANIZATION	1g. ORGANIZATIONAL ID#, if any	
		Corporation	Delaware	<input type="checkbox"/> NONE	

2. ADDITIONAL DEBTOR'S EXACT FULL LEGAL NAME - insert only one debtor name (2a or 2b) - do not abbreviate or combine names

2a. ORGANIZATION'S NAME					
OR	2b. INDIVIDUAL'S LAST NAME		FIRST NAME	MIDDLE NAME	SUFFIX
2c. MAILING ADDRESS		CITY	STATE	POSTAL CODE	COUNTRY
ADD'L INFO RE ORGANIZATION DEBTOR		2a. TYPE OF ORGANIZATION	2f. JURISDICTION OF ORGANIZATION	2g. ORGANIZATIONAL ID#, if any	
				<input type="checkbox"/> NONE	

3. SECURED PARTY'S NAME (or NAME of TOTAL ASSIGNEE of ASSIGNOR S/P) - insert only one secured party name (3a or 3b)

3a. ORGANIZATION'S NAME					
VINDRAUGA CORPORATION, a California corporation					
OR	3b. INDIVIDUAL'S LAST NAME		FIRST NAME	MIDDLE NAME	SUFFIX
3c. MAILING ADDRESS		CITY	STATE	POSTAL CODE	COUNTRY
1565 Hotel Circle South, Suite 310		San Diego	CA	92108	USA

4. This FINANCING STATEMENT covers the following collateral:

See Attachment "A"

5. ALTERNATIVE DESIGNATION (if applicable): <input type="checkbox"/> LESSEE/LESSOR <input type="checkbox"/> CONSIGNEE/CONSIGNOR <input type="checkbox"/> BAILEE/BAILOR <input type="checkbox"/> SELLER/BUYER <input type="checkbox"/> AG. LIEN <input type="checkbox"/> NON-UCC FILING	
6. <input type="checkbox"/> This FINANCING STATEMENT is to be filed (for record) (or recorded) in the REAL ESTATE RECORDS. Attach Addendum (if applicable)	
7. Check to REQUEST SEARCH REPORT(S) on Debtor(s) <input type="checkbox"/> All Debtors <input type="checkbox"/> Debtor 1 <input type="checkbox"/> Debtor 2 (optional)	
8. OPTIONAL FILER REFERENCE DATA	
P:\15\15534\71088\Trans\UCC-1 IP Security Agmt	

FILING OFFICE COPY - NATIONAL UCC FINANCING STATEMENT (FORM UCC1) - CALIFORNIA (REV. 01/01/08)

PATENT
REEL: 038831 FRAME: 0202

Debtor: RIDGE DIAGNOSTICS, INC., a Delaware corporation

Secured Party: VINDRAUGA CORPORATION, a California corporation

ATTACHMENT "A" TO UCC FINANCING STATEMENT

This Financing Statement encumbers Debtor's current and future, right, title and interest in and to:

(a) Trademark Collateral. (i) All common law, state, federal and internationally registered trademarks, service marks, trade names, corporate names, company names, business names, fictitious business names, product names, slogans, trade styles, trade dress, color marks and designs, logos, domain names, other source or business identifiers, designs and general intangibles of like nature, now existing or hereafter adopted or acquired in any way relating to the business of Debtor ("Business") or otherwise, together with and including all licenses therefor held by Debtor, and all registrations and recordings thereof, and all applications filed or to be filed in connection therewith, and all extensions and renewals thereof, including, without limitation any of the foregoing identified on Schedule "A" hereto (as the same may be amended, modified or supplemented from time to time), together with the goodwill of the Business symbolized by or associated with all of the foregoing (collectively, the "Trademarks"); (ii) all modifications, variations, derivative marks and names based upon the Trademarks used in Debtor's Business now or in the future, and the goodwill of the Business associated with such names and marks or other Trademarks; (iii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the Trademarks, including license fees and royalties under license and other agreements; (iv) all claims, causes of action, damages and recoveries for past, present and future infringements or unauthorized use of any of the Trademarks and all rights arising therefrom and pertaining thereto; (v) all rights corresponding to the Trademarks throughout the world; (vi) all general intangibles (as defined in the UCC) and all intangible intellectual property or other similar property of Debtor of any kind or nature, whether now owned or hereafter acquired or used, associated with or arising out of any of the Trademarks (including without limitation all license, distributorship and/or franchise agreements and rights under any "Existing Interests" as defined in that certain Intellectual Property Security Agreement dated November 7, 2013 between Debtor and Secured Party) not otherwise described herein and all of the goodwill of Debtor's Business symbolized by the Trademarks or associated therewith; (vii) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (viii) all Proceeds (as defined in the Intellectual Property Security Agreement) and products of any and all of the foregoing (all of the foregoing, collectively, the "Trademark Collateral").

(b) Trade Secret Collateral. (i) All trade secrets, confidential information, know-how and other intellectual property used in the Business of Debtor now or in the future and all renewals, modifications, derivatives and improvements relating thereto (collectively, the "Trade Secrets"); (ii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the Trade Secrets, including license fees and royalties under license and other agreements; (iii) all claims, causes of action, damages and recoveries for past, present and future infringements or unauthorized use of any of the Trade Secrets and all rights arising therefrom and pertaining thereto; (iv) all rights corresponding to the Trade Secrets throughout the world; (v) all general intangibles (as defined in the UCC) and all intangible intellectual property or other

Debtor: RIDGE DIAGNOSTICS, INC., a Delaware corporation

Secured Party: VINDRAUGA CORPORATION, a California corporation

similar property of Debtor of any kind or nature, whether now owned or hereafter acquired or developed, associated with or arising out of the Trade Secrets (including without limitation all license, distributorship and/or franchise agreements and rights under any Existing Interests) and not otherwise described herein; (vi) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (vii) all Proceeds and products of any and all of the foregoing (all of the foregoing, collectively, the "Trade Secret Collateral").

(c) Copyright Collateral. (i) All published and unpublished works of authorship that Debtor owns or uses in its Business or will in the future adopt and so use (including all advertising and promotional materials, franchise agreements and franchise operation manuals) all original and derivative works of authorship and works protectable by copyright that are presently or in the future may be, owned, created, authored, acquired or used (pursuant to a license or otherwise) by Debtor or by its employees, independent contractors, third parties or acquired by Debtor, all of Debtor's proprietary object code, source code, source data files and documentation in any way related to the Business and any modifications and derivative works related thereto, all copyright registrations and applications for copyright registration that previously have been or may hereafter be issued thereon or applied for in the U.S. or anywhere in the world, all registrations resulting from such copyright applications, and all renewals, modifications, extensions, derivative works and collective works thereof or related to any of the foregoing, throughout the world, together with all copyright licenses held by Debtor, and all common law rights, copyrights, rights of authorship and moral rights related to any of the foregoing, including without limitation, any of the foregoing identified on Schedule "A" hereto (as the same may be amended, modified or supplemented from time to time) (collectively, the "Copyrights"); (ii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the foregoing, including license fees and royalties under license and other agreements; (iii) all claims, causes of action, damages and recoveries for past, present and future infringements or unauthorized use of any of the Copyrights and all rights arising therefrom and pertaining thereto; (iv) all rights corresponding to the Copyrights throughout the world; (v) all general intangibles (as defined in the UCC) and all intangible intellectual property or other similar property of Debtor of any kind or nature, whether now owned or hereafter acquired or developed, associated with or arising out of any of the Copyrights (including without limitation all license, distributorship and/or franchise agreements and rights under any Existing Interests) and not otherwise described herein; (vi) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (vii) all Proceeds and products of any and all of the foregoing (all of the foregoing, collectively, the "Copyright Collateral").

(d) Patent Collateral. (i) All patents and patent applications (including, without limitation, the inventions, devices, specifications and improvements described and claims therein) filed in the U.S. or in any other country, owned, held or used by Debtor in whole or in part, and all patent and invention disclosures related thereto, together with all reissuances, divisions, continuations, continuations-in-part, renewals, extensions, re-examinations, supplementary protection certificates, modifications, derivatives and improvements thereof and the inventions disclosed therein, and all new or separate patents that may be issued in connection with the foregoing, and all other inventions (whether patentable or unpatentable, whether or not reduced

Debtor: RIDGE DIAGNOSTICS, INC., a Delaware corporation

Secured Party: VINDRAUGA CORPORATION, a California corporation

to practice or developed alone or jointly with others), and together with and including all patent licenses held by Debtor, and all other rights, including the right to make, use, license, sell, exploit and otherwise transfer the inventions disclosed therein, including without limitation, any of the foregoing identified on Schedule "A" hereto (as the same may be amended, modified or supplemented from time to time) (collectively the "Patents"); (ii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the Patents, including license fees and royalties under license and other agreements; (iii) all claims, causes of action, damages and recoveries for past, present and future infringements thereof or unauthorized use of any of the Patents and all rights arising therefrom and pertaining thereto; (iv) all rights corresponding to the Patents throughout the world; (v) all general intangibles (as defined in the UCC) and all intangible intellectual property or other similar property of Debtor of any kind or nature, whether now owned or hereafter acquired or developed, associated with or arising out of any of the Patents (including without limitation all license, distributorship and/or franchise agreements and rights under any Existing Interests) and not otherwise described herein; (vi) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (vii) all products and Proceeds of any and all of the foregoing (all of the foregoing, collectively, the "Patent Collateral").

Debtor: RIDGE DIAGNOSTICS, INC., a Delaware corporation

Secured Party: VINDRAUGA CORPORATION, a California corporation

SCHEDULE A TO ATTACHMENT "A" TO UCC FINANCING STATEMENT

Without limiting the generality of the foregoing, this Financing Statement encumbers Debtor's current and future, right, title and interest in and to the following trademarks and patents to the fullest extent permitted under applicable law:

[See Attached Page(s)]

Schedule A to the Intellectual Property Security Agreement

Ridge Diagnostics, Inc
Intellectual Property Status List
As at 4 Oct 2013

F&R Ref.	Country	Serial No.	Filing Date	Pub. No.	Pub. Date	Patent No.	Issue Date	Status
Molecular Interaction Measurement Chip and System								
20436-0004P01	US	60/748,824	9-Dec-2005	-	-	-	-	Expired (converted to PCT)
20436-0004US1	US	12/305,950	19-Dec-2008	2010-0144052	10-Dec-2010	-	-	Pending
20436-0004WO1	WIPO	PCT/US2006/047244	11-Dec-2006	WO 2007/067819	14-Jun-2007	-	-	Expired (national phase)
Molecular Interaction Detection Chip and Fabrication Process								
20436-0005P01	US	60/784,322	21-Mar-2006	-	-	-	-	Expired (converted to PCT (0004WO1))
Precision Molecular Interaction Measurement System and Method								
20436-0006P01	US	60/796,585	1-May-2006	-	-	-	-	Expired (converted to PCT (0004WO1))
Quantitative Diagnostic Methods Using Multiple Parameters								
20436-0007001	US	11/850,550	5-Sep-2007	-	-	8,158,374	17-Apr-2012	Issued
20436-0007002	US	13/446,382	13-Apr-2012	2012-0289422	15-Nov-2012	8,450,077	28-May-2013	Issued
20436-0007003	US	13/903,346	28-May-2013	-	-	-	-	Pending
20436-0007P01	US	60/824,471	5-Sep-2006	-	-	-	-	Expired (converted to utility)
Diagnostics with multiple parameters - algorithm and methods								
20436-0008P01	US	60/810,217	5-Apr-2007	-	-	-	-	Expired (converted to utility (0007001))
Diagnostics with multiple parameters - algorithm and methods								
20436-0009P01	US	61/033,726	4-Mar-2008	-	-	-	-	Expired (converted to PCT)
20436-0009WO1	WIPO	PCT/US2009/036084	4-Mar-2009	WO 2009/111595	11-Sep-2009	-	-	Expired (national phase)
20436-0009CA1	Canada	2717763	4-Mar-2009	-	-	-	-	Pending
20436-0009CN1	China	200980115931.3	4-Mar-2009	CN10203755A	27-Apr-2011	-	-	Pending
20436-0009EP1	Europe	9717234	4-Mar-2009	2329280	8-Jun-2011	-	-	Pending
20436-0009JP1	Japan	2010-549883	4-Mar-2009	2011-518318	23-Jun-2011	-	-	Pending
20436-0009US1	US	12/921,349	4-Mar-2009	2011-0245092	6-Oct-2011	-	-	Pending
Combinations of Selected Biomarkers for Diagnosing Depressive Disorders								
20436-0010P01	US	61/033,721	4-Mar-2008	-	-	-	-	Expired (converted to PCT (0009WO1))
Monitoring Depressive Disorders Based on Hypothalamic-Pituitary-Adrenal (HPA) Axis Biomarkers								
20436-0011P01	US	61/033,731	4-Mar-2008	-	-	-	-	Expired (converted to PCT (0009WO1))
Inflammatory Biomarkers for Monitoring Depressive Disorders								
20436-0012P01	US	61/036,013	12-Mar-2008	-	-	-	-	Expired (converted to PCT)
20436-0012WO1	WIPO	PCT/US2009/036833	11-Mar-2009	WO 2009/114827	17-Sep-2009	-	-	Expired (national phase)
20436-0012CA1	Canada	2718273	11-Mar-2009	-	-	-	-	Pending
20436-0012CN1	China	200980116135.1	11-Mar-2009	CN 102016907A	13-Apr-2011	-	-	Pending
20436-0012EP1	Europe	9718958.3	11-Mar-2009	2272044	12-Jan-2011	-	-	Pending
20436-0012HK1	Hong Kong	11107199.1	12-Jul-2011	1153282	23-Mar-2012	-	-	Pending
20436-0012JP1	Japan	2010-550839	11-Mar-2009	2011-520095	14-Jul-2011	-	-	Pending
20436-0012US1	US	12/922,365	11-Mar-2009	2011-0269833	3-Nov-2011	-	-	Pending
Human Biomarker Hypomapping for Depressive Disorders								
20436-0013P01	US	61/105,841	15-Oct-2008	-	-	-	-	Expired (converted to PCT and utility)
20436-0013001	US	12/579,733	15-Oct-2009	2010-0100333	22-Apr-2010	-	-	Pending
20436-0013WO1	WIPO	PCT/US2009/060895	15-Oct-2009	WO 2007/030475	15-Mar-2007	-	-	Expired (national phase)
20436-0013CA1	Canada	2740736	15-Oct-2009	-	-	-	-	Pending
20436-0013CN1	China	200980147037.4	15-Oct-2009	CN 102257157A	23-Nov-2011	-	-	Pending

20436-0013EP1	Europe	9821274.9	15-Oct-2008	2337866	29-Jun-2011	-	-	Pending
20436-0013HK1	Hong Kong	12105066.4	15-Oct-2009	1164379	21-Sep-2012	-	-	Pending
20436-0013JP1	Japan	2011-0532262	15-Oct-2009	2012-506053	8-Mar-2012	-	-	Pending
Combinations of Metabolic Syndrome and HPA Axis Biomarkers for Monitoring Major Depressive Disorder								
20436-0014P01	US	61/115,710	18-Nov-2008	-	-	-	-	Expired (converted to PCT and utility)
20436-0014001	US	12/620,831	18-Nov-2009	2010-0136700	3-Jun-2010	8,440,418	14-May-2013	Issued
20436-0014002	US	13/892,714	13-May-2013	-	-	-	-	Pending
20436-0014WO1	WIPO	PCT/US2009/064967	18-Nov-2009	WO 2010/059709	27-May-2010	-	-	Expired (national phase)
20436-0014CA1	Canada	2744151	18-Nov-2009	-	-	-	-	Pending
20436-0014CN1	China	200980153799.5	18-Nov-2009	CN 102301234A	28-Dec-2011	-	-	Pending
20436-0014EP1	Europe	9828159.5	18-Nov-2009	2356453	17-Aug-2011	-	-	Pending
20436-0014HK1	Hong Kong	12108344.6	18-Nov-2009	1165554	5-Oct-2012	-	-	Pending
20436-0014JP1	Japan	2011-537577	18-Nov-2009	2012-509480	19-Apr-2012	-	-	Pending
Biomarker Panels for Stratifying and Monitoring Major Depressive Disorder								
20436-0015P01	US	61/298,443	26-Jan-2010	-	-	-	-	Expired (converted to PCT and utility)
20436-0015001	US	13/014,413	26-Jan-2011	2011-0213219	1-Sep-2011	-	-	Pending
20436-0015WO1	WIPO	PCT/US2011/022573	26-Jan-2011	WO 2011/094308	4-Aug-2011	-	-	Expired (national phase)
20436-0015CA1	Canada	2788315	26-Jan-2011	-	-	-	-	Pending
20436-0015CN1	China	201180011737.8	26-Jan-2011	CN 102884428A	16-Jan-2013	-	-	Pending
20436-0015EP1	Europe	11737575.8	26-Jan-2011	2529222	5-Dec-2012	-	-	Pending
20436-0015JP1	Japan	2012-551263	26-Jan-2011	2013-518287	20-May-2013	-	-	Pending
Biomarkers for Monitoring Treatment of Neuropsychiatric Diseases								
20436-0016P01	US	61/165,662	1-Apr-2009	-	-	-	-	Expired (converted to PCT and utility)
20436-0016001	US	12/753,022	1-Apr-2010	2010-0280760	4-Nov-2010	-	-	Pending
20436-0016WO1	WIPO	PCT/US2010/029720	1-Apr-2010	WO 2010/0115061	7-Oct-2010	-	-	Expired (national phase)
20436-0016CA1	Canada	2757518	1-Apr-2010	-	-	-	-	Pending
20436-0016CN1	China	201080022308.7	1-Apr-2010	CN 102483398A	30-May-2012	-	-	Pending
20436-0016EP1	Europe	10759446.7	1-Apr-2010	2414824	8-Feb-2012	-	-	Pending
20436-0016HK1	Hong Kong	12112408.7	1-Apr-2010	1171807	5-Apr-2013	-	-	Pending
20436-0016JP1	Japan	2012-503731	1-Apr-2010	2012-522995	27-Sep-2012	-	-	Pending
Biomarkers for Monitoring Treatment of Neuropsychiatric Diseases								
20436-0017P01	US	61/168,988	6-Apr-2009	-	-	-	-	Expired (converted to PCT and utility)
20436-0017001	US	12/754,770	6-Apr-2010	2010-0280582	4-Nov-2010	-	-	Pending
20436-0017WO1	WIPO	PCT/US2010/030104	6-Apr-2010	WO 2010/118035	14-Oct-2010	-	-	Expired (national phase)
20436-0017CA1	Canada	2757659	6-Apr-2010	-	-	-	-	Pending
20436-0017CN1	China	2010800252866.8	6-Apr-2010	CN 102460153A	16-May-2012	-	-	Pending
20436-0017EP1	Europe	10762304.3	6-Apr-2010	2417448	18-Feb-2012	-	-	Pending
20436-0017NK	Hong Kong	12111712.0	6-Apr-2010	1171081	15-Mar-2013	-	-	Pending
20436-0017JP1	Japan	2012-504782	6-Apr-2010	2012-523009	27-Sep-2012	-	-	Pending
Human Biomarker Test for Major Depressive Disorder								
20436-0018P01	US	61/798,910	15-Mar-2013	-	-	-	-	Pending
Biomarkers for Monitoring Treatment of Neuropsychiatric Diseases								
20436-0020P01	US	61/420,141	6-Dec-2010	-	-	-	-	Expired (converted to PCT and utility)
20436-0020001	US	13/312,553	6-Dec-2011	2012-0178118	7/12/2012	-	-	Pending
20436-0020WO1	WIPO	PCT/US2011/063522	6-Dec-2011	-	-	-	-	Expired (national phase)
20436-0020CA1	Canada	2820618	6-Dec-2011	-	-	-	-	Pending
20436-0020CN1	China	201180068505.2	6-Dec-2011	-	-	-	-	Pending
20436-0020EP1	Europe	11846638.2	6-Dec-2011	-	-	-	-	Pending
20436-0020JP1	Japan	unknown	6-Dec-2011	-	-	-	-	Pending
Trademarks								
Serial Number	Reg. Number	Word Mark	Check Status	Live/Dead	Registration Date			
85264705	4117318	RIDGE DIAGNOSTICS	TSDR	LIVE	3/27/2012			
85264659	4117317	RIDGE DIAGNOSTICS	TSDR	LIVE	3/27/2012			

Exhibit 4

UCC FINANCING STATEMENT AMENDMENT

FOLLOW INSTRUCTIONS

DELAWARE DEPARTMENT OF STATE
U.C.C. FILING SECTION
FILED 02:21 PM 04/23/2015
INITIAL FILING # 2013 4419884
AMENDMENT # 2015 1744746
SRV: 150556009

A. NAME & PHONE OF CONTACT AT FILER (optional) Joseph P. Martinez, Esq., (619) 685-3177; Fax: (619) 702-6857
B. E-MAIL CONTACT AT FILER (optional) martinez@scmv.com
C. SEND ACKNOWLEDGMENT TO: (Name and Address) Seltzer Caplan McMahon Vitek 750 B Street, Suite 2100 San Diego, California 92101 Attn: Joseph P. Martinez, Esq.

THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY

1a. INITIAL FINANCING STATEMENT FILE NUMBER
20134419884

1b. ☐ This FINANCING STATEMENT AMENDMENT is to be filed (for record) (or recorded) in the REAL ESTATE RECORDS
Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor's name in item 13

2. ☐ TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement

3. ☐ ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 9
For partial assignment, complete items 7 and 9 and also indicate affected collateral in item 8

4. ☐ CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law

5. ☒ PARTY INFORMATION CHANGE:
Check one of these two boxes: ☒ Debtor or ☐ Secured Party of record
AND Check one of these three boxes to:
☒ CHANGE name and/or address: Complete item 6a or 6b; and item 7a or 7b and item 7c ☐ ADD name: Complete item 7a or 7b, and item 7c ☐ DELETE name: Give record name to be deleted in item 6a or 6b

6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b)

6a. ORGANIZATION'S NAME RIDGE DIAGNOSTICS, INC., a Delaware corporation	OR	6b. INDIVIDUAL'S SURNAME	FIRST PERSONAL NAME	ADDITIONAL NAME(S)/INITIAL(S)	SUFFIX
---	----	--------------------------	---------------------	-------------------------------	--------

7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor's name)

7a. ORGANIZATION'S NAME RIDGE DIAGNOSTICS, INC.	OR	7b. INDIVIDUAL'S SURNAME
INDIVIDUAL'S FIRST PERSONAL NAME		
INDIVIDUAL'S ADDITIONAL NAME(S)/INITIAL(S)		
SUFFIX		

7c. MAILING ADDRESS 4225 Executive Square, Suite 600	CITY La Jolla	STATE CA	POSTAL CODE 92037	COUNTRY USA
--	-------------------------	--------------------	-----------------------------	-----------------------

8. ☐ COLLATERAL CHANGE: Also check one of these four boxes: ☐ ADD collateral ☐ DELETE collateral ☐ RESTATE covered collateral ☐ ASSIGN collateral
Indicate collateral:

9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment)
If this is an Amendment authorized by a DEBTOR, check here ☐ and provide name of authorizing Debtor

9a. ORGANIZATION'S NAME VINDRAUGA CORPORATION	OR	9b. INDIVIDUAL'S SURNAME	FIRST PERSONAL NAME	ADDITIONAL NAME(S)/INITIAL(S)	SUFFIX
---	----	--------------------------	---------------------	-------------------------------	--------

10. OPTIONAL FILER REFERENCE DATA:
P:\15\15534\71088\Trans\UCC-3 IP Security Agreement

FILING OFFICE COPY — UCC FINANCING STATEMENT AMENDMENT (Form UCC3) (Rev. 04/20/11)

International Association of Commercial Administrators (IACA)

PATENT
REEL: 038831 FRAME: 0210

Exhibit 5


ASSIGNMENT OF DEBT

For good and valuable consideration, receipt of which is hereby acknowledged, VINDRAUGA CORPORATION ("Assignor") hereby assigns and transfers to VINDRAUGA HOLDINGS, LLC ("Assignee") without recourse, that certain "Second Amended and Restated Convertible Promissory Note" dated as of January 27, 2015 in the stated principal amount of \$2,570,000.00, executed by Ridge Diagnostics, Inc. as Borrower and payable to Vindrauga Corporation as Lender, and the debt represented thereby, all incidents of such debt, all documents executed in connection therewith, and all rights thereunder, including without implied limitation the following: (i) Loan Agreement dated as of November 7, 2013, as amended by the First Amendment to Loan Agreement dated as of April 28, 2014 and as further amended by the Second Amendment to Loan Agreement dated as of January 27, 2015; (ii) those documents referred to collectively in the Loan Agreement as the "Security Instrument" including the "Security Agreement (Blanket)" dated as of November 7, 2013, and the "Intellectual Property Security Agreement" of even date, and all other documents and instruments that create a security interest or assignment for the purposes of securing the debt, as any of the foregoing may be amended, restated, replaced, supplemented or otherwise modified from time to time.

DATE: April 4, 2016

"ASSIGNOR"

VINDRAUGA CORPORATION
A California corporation

By: 
James R. Wade
President

The above assignment is accepted.

"ASSIGNEE"

VINDRAUGA HOLDINGS, LLC
A California limited liability company
By: DACA GP, LLC
A California limited liability company
Its Managing Member


By: 
Howard Justus, Managing Member

Exhibit 6

UCC FINANCING STATEMENT AMENDMENT

FOLLOW INSTRUCTIONS

A. NAME & PHONE OF CONTACT AT FILER (optional) Dean T. Kirby, Jr.
B. E-MAIL CONTACT AT FILER (optional) dkirby@kirbymac.com
C. SEND ACKNOWLEDGMENT TO: (Name and Address) KIRBY & McGUINN, A P.C. 707 Broadway, Suite 1750 San Diego, CA 92101

Delaware Department of State
U.C.C. Filing Section
Filed: 05:36 PM 04/04/2016
U.C.C. Initial Filing No: 2013 4419884
Amendment No: 20161991577
Service Request No: 20162064622

THE ABOVE SPACE IS FOR FILING OFFICE USE ONLY

1a. INITIAL FINANCING STATEMENT FILE NUMBER
20134419884

1b. ☐ This FINANCING STATEMENT AMENDMENT is to be filed [for record] (or recorded) in the REAL ESTATE RECORDS
Filer: attach Amendment Addendum (Form UCC3Ad) and provide Debtor's name in item 13

2. ☐ TERMINATION: Effectiveness of the Financing Statement identified above is terminated with respect to the security interest(s) of Secured Party authorizing this Termination Statement

3. ☐ ASSIGNMENT (full or partial): Provide name of Assignee in item 7a or 7b, and address of Assignee in item 7c and name of Assignor in item 8
For partial assignment, complete items 7 and 8 and also indicate affected collateral in item 8

4. ☐ CONTINUATION: Effectiveness of the Financing Statement identified above with respect to the security interest(s) of Secured Party authorizing this Continuation Statement is continued for the additional period provided by applicable law

5. ☒ PARTY INFORMATION CHANGE:

Check one of these two boxes:

AND Check one of these three boxes to:

This Change affects ☐ Debtor or ☒ Secured Party of record

☒ CHANGE name and/or address: Complete item 6a or 6b; and item 7a or 7b and item 7c

☐ ADD name: Complete item 7a or 7b, and item 7c

☐ DELETE name: Give record name to be deleted in item 6a or 6b

6. CURRENT RECORD INFORMATION: Complete for Party Information Change - provide only one name (6a or 6b)

6a. ORGANIZATION'S NAME Vindrauga Corporation	OR		
6b. INDIVIDUAL'S SURNAME	FIRST PERSONAL NAME	ADDITIONAL NAME(S)/INITIAL(S)	SUFFIX

7. CHANGED OR ADDED INFORMATION: Complete for Assignment or Party Information Change - provide only one name (7a or 7b) (use exact, full name; do not omit, modify, or abbreviate any part of the Debtor's name)

7a. ORGANIZATION'S NAME Vindrauga Holdings, LLC	OR		
7b. INDIVIDUAL'S SURNAME	INDIVIDUAL'S FIRST PERSONAL NAME		
	INDIVIDUAL'S ADDITIONAL NAME(S)/INITIAL(S)		
	SUFFIX		

7c. MAILING ADDRESS 1565 Hotel Circle South, Suite 310	CITY San Diego	STATE CA	POSTAL CODE 92108	COUNTRY USA
---	-------------------	-------------	----------------------	----------------

8. ☐ COLLATERAL CHANGE: Also check one of these four boxes: ☐ ADD collateral ☐ DELETE collateral ☐ RESTATE covered collateral ☐ ASSIGN collateral
Indicate collateral:

9. NAME OF SECURED PARTY OF RECORD AUTHORIZING THIS AMENDMENT: Provide only one name (9a or 9b) (name of Assignor, if this is an Assignment)

If this is an Amendment authorized by a DEBTOR, check here ☐ and provide name of authorizing Debtor

9a. ORGANIZATION'S NAME Vindrauga Corporation	OR		
9b. INDIVIDUAL'S SURNAME	FIRST PERSONAL NAME	ADDITIONAL NAME(S)/INITIAL(S)	SUFFIX

10. OPTIONAL FILER REFERENCE DATA:

Exhibit 7

NOTIFICATION OF INTENDED DISPOSITION OF COLLATERAL

To: Ridge Diagnostics, Inc., a Delaware corporation (Debtor)

From: Vindrauga Corporation (Secured Party)
1565 Hotel Circle South, Suite 310
San Diego, CA 92108
Attn: James Wade jwade@daca4.com
(619) 220-8900 Ext. 114

We (the Secured Party) will sell the Collateral described below to the highest qualified bidder in public as follows:

Day and Date: April 5, 2016

Time: 10:00 a.m.

Place: Kirby & McGuinn
707 Broadway, Suite 1750
San Diego, CA 92101
Attn: Dean T. Kirby, Jr. dkirby@kirbymac.com
(619) 525-1652

We reserve the right to purchase at the sale, and to continue or postpone the sale by announcement made at the above date, time and place. The opening credit bid will be \$3,000,000.00.

You (the Debtor) are entitled to an accounting of the unpaid indebtedness secured by the property that we intend to sell. You may request an accounting by calling us at 619-220-8900 Ext. 114.

All Collateral will be sold, as a single lot, without representation or warranty, "as is" and "with all faults." and at its current locations. The Collateral includes all personal property identified in the following financing statements on file with the Delaware Secretary of State: (i) Filing No. 2013-4419959 filed 11/8/13, as amended by Filing No. 2015-1744720; and (ii) Filing No. 2013-4419884, as amended by Filing No. 2015-1744746.

The security interest of Secured Party has been subordinated to, and the Collateral will be sold subject to, a lien securing a loan described in that certain Intercreditor Agreement dated as of June 1, 2015 as the "Interim Funding Loan." The approximate balance secured by the senior lien is \$983,427.52 as of the date of this Notice.

The security interest of Secured Party is of equal priority to a lien securing a loan described in the Intercreditor Agreement as the "Bridge Loan." The security interest securing the Bridge Loan was perfected by the filing of a financing statement (Filing No. 2015 0740299 filed 2/22/15) with the Delaware Secretary of State. The auction sale will be contingent upon the release of this co-equal lien by the Bridge Lenders. All cash received in connection with the bidding will be held in trust by Kirby & McGuinn until the earliest of the following: (i) lien releases reasonably satisfactory to the successful bidder are held by Kirby & McGuinn for the successful bidder; or (ii) seven days after the conclusion of the auction.

The Collateral to be sold includes the following, without implied limitation of the description in the above-referenced financing statements:

All of the Debtor's personal fixture property, and interests therein, and interests in fixture property, of every kind and nature, whether owned at the creation of the security interest or thereafter acquired or arising, and wherever located, including the following properties, assets and rights of the Debtor: (i) Accounts; (ii) Chattel Paper; (ii) Commercial Tort Claims; (iv) Deposit Accounts; (v) Documents; (vi) Equipment; (vii) General Intangibles; (viii) Goods; (ix) Instruments; (x) Investment Property; (xi) Inventory; (xii) Letter of Credit Rights; (xiii) Supporting Obligations; (ix) Debtor's other personal property and rights of every kind and interests therein; (xiv) (p) all property delivered to Secured Party by Debtor or other of Debtor's property that shall otherwise be in Secured Party's possession or control in any manner or for any purpose.

All Trademark Collateral, Trade Secret Collateral, Copyright Collateral and Patent Collateral as described in the above-referenced financing statement Filing No. Filing No. 2013-4419884, as amended by Filing No. 2015-1744746, including without implied limitation U.S. Patent Nos. 8,158,374, 8,440,418 and 8,450,077.

And: (a) all books, records, writings, data bases, information and other property relating to, used or useful in connection with, evidencing, embodying, incorporating or referring to, any of the foregoing; (b) all Proceeds, products, substitutes and replacements of such property; all additions, attachments and Accessions to any of the foregoing; and (c) all property which the Debtor may receive on account of and from any and all of the foregoing.

DATE: March 22, 2016

/s/ Dean T. Kirby, Jr.
Attorney for Secured Party

Exhibit 8

SECURED PARTY BILL OF SALE

April 5, 2016

As a disposition of collateral at public sale pursuant to the section 9610 of the California Commercial Code, the undersigned Seller / Secured Party does hereby grant, sell, assign, transfer and convey unto itself as Buyer, and to its successors and assigns, in consideration of a partial credit bid of the secured indebtedness in the amount of Three Million and 00/100 Dollars, (\$3,000,000.00) all right, title and interest of Ridge Diagnostics, Inc., a Delaware Corporation (the "Debtor") in the Collateral described in Exhibit A to this Bill of Sale, subject to all of the terms and conditions stated herein.

IN WITNESS WHEREOF Secured Party has executed this Bill of Sale as of the date first above written.


VINDRAUGA HOLDINGS, LLC

A California limited liability company

By: DACA GP, LLC

A California limited liability company

Its Managing Member

By: 

Howard Justus, Managing Member

PATENT

REEL: 038831 FRAME: 0219

///
///
///
///
///
///
///
///
///
This Financing Statement encumbers Debtor's current and future, right, title and interest in and to:

All of Debtor's personal and fixture property, and interests therein, of every kind and nature, whether now owned or hereafter acquired or arising, and wherever located, including all of the following properties, assets and rights of Debtor:

- (a) all Accounts;
- (b) all Chattel Paper;
- (c) all Commercial Tort Claims;
- (d) all Deposit Accounts;
- (e) all Documents;
- (f) all Equipment;
- (g) all Fixtures;
- (h) all General Intangibles;
- (i) all Goods;
- (j) all Instruments;
- (k) all Investment Property;
- (l) all Inventory;
- (m) all Letter-of-Credit Rights;
- (n) all Supporting Obligations;
- (o) all of Debtor's other personal property and rights of every kind and description and interests therein;
- (p) all property delivered to Secured Party by Debtor or other of Debtor's property that shall otherwise be in Secured Party's possession or control in any manner or for any purpose;

///

///

///

(q) all books, records, writings, data bases, information and other property relating to, used or useful in connection with, evidencing, embodying, incorporating or referring to, any of the foregoing; and

(r) all Proceeds, products, substitutes and replacements of such property; all additions, attachments and Accessions to any of the foregoing; and all property which Debtor may receive on account of and from any and all of the foregoing.

For avoidance of doubt it is expressly understood and agreed that the Collateral is intended to consist of all personal and fixture property of Debtor, and to the extent the UCC is revised subsequent to the date hereof such that the definition of any of the foregoing terms included in the description of Collateral is changed, the parties agree that any property which is included in such changed definitions which would not otherwise be included in the foregoing grant on the date hereof be included in such grant immediately upon the effective date of such revision, it being the intention of the parties hereto that the description of Collateral set forth herein be construed to include the broadest possible range of property and assets and all tangible and intangible personal property and fixtures of Debtor of every kind and description.

///

///

///

///

///

///

///

///
///
///
///
///
///
///

This Financing Statement encumbers Debtor's current and future, right, title and interest in and to:

(a) Trademark Collateral. (i) All common law, state, federal and internationally registered trademarks, service marks, trade names, corporate names, company names, business names, fictitious business names, product names, slogans, trade styles, trade dress, color marks and designs, logos, domain names, other source or business identifiers, designs and general intangibles of like nature, now existing or hereafter adopted or acquired in any way relating to the business of Debtor ("Business") or otherwise, together with and including all licenses therefor held by Debtor, and all registrations and recordings thereof, and all applications filed or to be filed in connection therewith, and all extensions and renewals thereof, including, without limitation any of the foregoing identified on Schedule "A" hereto (as the same may be amended, modified or supplemented from time to time), together with the goodwill of the Business symbolized by or associated with all of the foregoing (collectively, the "Trademarks"); (ii) all modifications, variations, derivative marks and names based upon the Trademarks used in Debtor's Business now or in the future, and the goodwill of the Business associated with such names and marks or other Trademarks; (iii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the Trademarks, including license fees and royalties under license and other agreements; (iv) all claims, causes of action, damages and recoveries for past, present and future infringements or unauthorized use of any of the Trademarks and all rights arising therefrom and pertaining thereto; (v) all rights corresponding to the Trademarks throughout the world; (vi) all general intangibles (as defined in the UCC) and all intangible intellectual property or other similar property of Debtor of any kind or nature, whether now owned or hereafter acquired or used, associated with or arising out of any of the Trademarks (including without limitation all license, distributorship and/or franchise agreements and rights under any "Existing Interests" as defined in that certain Intellectual Property Security Agreement dated November 7, 2013 between Debtor and Secured Party) not otherwise described herein and all of the goodwill of Debtor's Business symbolized by the Trademarks or associated therewith; (vii) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (viii) all Proceeds (as defined in the Intellectual Property Security Agreement) and products of any and all of the foregoing (all of the foregoing, collectively, the "Trademark Collateral").

(b) Trade Secret Collateral. (i) All trade secrets, confidential information, know-how and other intellectual property used in the Business of Debtor now or in the future and all renewals, modifications, derivatives and improvements relating thereto (collectively, the "Trade Secrets"); (ii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the Trade Secrets, including license fees and royalties under license and other agreements; (iii) all claims, causes of action, damages and recoveries for past, present and future infringements or unauthorized use of any of the Trade Secrets and all rights arising therefrom and pertaining thereto; (iv) all rights corresponding to the Trade Secrets throughout the world; (v) all general intangibles (as defined in the UCC) and all intangible intellectual property or other

///
///
///
///

similar property of Debtor of any kind or nature, whether now owned or hereafter acquired or developed, associated with or arising out of the Trade Secrets (including without limitation all license, distributorship and/or franchise agreements and rights under any Existing Interests) and not otherwise described herein; (vi) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (vii) all Proceeds and products of any and all of the foregoing (all of the foregoing, collectively, the "Trade Secret Collateral").

(c) Copyright Collateral. (i) All published and unpublished works of authorship that Debtor owns or uses in its Business or will in the future adopt and so use (including all advertising and promotional materials, franchise agreements and franchise operation manuals) all original and derivative works of authorship and works protectable by copyright that are presently or in the future may be, owned, created, authored, acquired or used (pursuant to a license or otherwise) by Debtor or by its employees, independent contractors, third parties or acquired by Debtor, all of Debtor's proprietary object code, source code, source data files and documentation in any way related to the Business and any modifications and derivative works related thereto, all copyright registrations and applications for copyright registration that previously have been or may hereafter be issued thereon or applied for in the U.S. or anywhere in the world, all registrations resulting from such copyright applications, and all renewals, modifications, extensions, derivative works and collective works thereof or related to any of the foregoing, throughout the world, together with all copyright licenses held by Debtor, and all common law rights, copyrights, rights of authorship and moral rights related to any of the foregoing, including without limitation, any of the foregoing identified on Schedule "A" hereto (as the same may be amended, modified or supplemented from time to time) (collectively, the "Copyrights"); (ii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the foregoing, including license fees and royalties under license and other agreements; (iii) all claims, causes of action, damages and recoveries for past, present and future infringements or unauthorized use of any of the Copyrights and all rights arising therefrom and pertaining thereto; (iv) all rights corresponding to the Copyrights throughout the world; (v) all general intangibles (as defined in the UCC) and all intangible intellectual property or other similar property of Debtor of any kind or nature, whether now owned or hereafter acquired or developed, associated with or arising out of any of the Copyrights (including without limitation all license, distributorship and/or franchise agreements and rights under any Existing Interests) and not otherwise described herein; (vi) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (vii) all Proceeds and products of any and all of the foregoing (all of the foregoing, collectively, the "Copyright Collateral").

(d) Patent Collateral. (i) All patents and patent applications (including, without limitation, the inventions, devices, specifications and improvements described and claims therein) filed in the U.S. or in any other country, owned, held or used by Debtor in whole or in part, and all patent and invention disclosures related thereto, together with all reissuances, divisions, continuations, continuations-in-part, renewals, extensions, re-examinations, supplementary protection certificates, modifications, derivatives and improvements thereof and the inventions disclosed therein, and all new or separate patents that may be issued in connection with the foregoing, and all other inventions (whether patentable or unpatentable, whether or not reduced

///
///
///
///

to practice or developed alone or jointly with others), and together with and including all patent licenses held by Debtor, and all other rights, including the right to make, use, license, sell, exploit and otherwise transfer the inventions disclosed therein, including without limitation, any of the foregoing identified on Schedule "A" hereto (as the same may be amended, modified or supplemented from time to time) (collectively the "Patents"); (ii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the Patents, including license fees and royalties under license and other agreements; (iii) all claims, causes of action, damages and recoveries for past, present and future infringements thereof or unauthorized use of any of the Patents and all rights arising therefrom and pertaining thereto; (iv) all rights corresponding to the Patents throughout the world; (v) all general intangibles (as defined in the UCC) and all intangible intellectual property or other similar property of Debtor of any kind or nature, whether now owned or hereafter acquired or developed, associated with or arising out of any of the Patents (including without limitation all license, distributorship and/or franchise agreements and rights under any Existing Interests) and not otherwise described herein; (vi) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (vii) all products and Proceeds of any and all of the foregoing (all of the foregoing, collectively, the "Patent Collateral").

///
///
///
///
///
///
///
///
///
///

///

///

///

///

Without limiting the generality of the foregoing, this Financing Statement encumbers Debtor's current and future, right, title and interest in and to the following trademarks and patents to the fullest extent permitted under applicable law:

[See Attached Page(s)]

Schedule A to the Intellectual Property Security Agreement

Ridge Diagnostics, Inc.
Intellectual Property Status List
As at 4 Oct 2013

F&R Ref.	Country	Serial No.	Filing Date	Pub. No.	Pub. Date	Patent No.	Issue Date	Status
Molecular Interaction Measurement Chip and System								
20438-0004P01	US	80/748,824	9-Dec-2006	-	-	-	-	Expired (converted to PCT)
20438-0004US1	US	12/305,850	19-Dec-2008	2010-0144052	10-Dec-2010	-	-	Pending
20438-0004WO1	WIPO	PCT/US2006/047244	11-Dec-2006	WO 2007/087819	14-Jun-2007	-	-	Expired (national phase)
Molecular Interaction Detection Chip and Fabrication Process								
20438-0005P01	US	80/784,322	21-Mar-2006	-	-	-	-	Expired (converted to PCT (0004WO1))
Precision Molecular Interaction Measurement System and Method								
20438-0006P01	US	80/796,585	1-May-2006	-	-	-	-	Expired (converted to PCT (0004WO1))
Quantitative Diagnostic Methods Using Multiple Parameters								
20438-0007001	US	11/850,550	5-Sep-2007	-	-	8,158,374	17-Apr-2012	Issued
20438-0007002	US	13/446,382	13-Apr-2012	2012-0280422	15-Nov-2012	8,450,077	25-May-2013	Issued
20438-0007003	US	13/003,346	28-May-2013	-	-	-	-	Pending
20438-0007P01	US	80/824,471	5-Sep-2006	-	-	-	-	Expired (converted to utility)
Diagnostics with multiple parameters - algorithm and methods								
20438-0008P01	US	80/810,217	5-Apr-2007	-	-	-	-	Expired (converted to utility (0007001))
Diagnostics with multiple parameters - algorithm and methods								
20438-0009P01	US	81/033,726	4-Mar-2008	-	-	-	-	Expired (converted to PCT)
20438-0009WO1	WIPO	PCT/US2008/036084	4-Mar-2008	WO 2009/111595	11-Sep-2009	-	-	Expired (national phase)
20438-0009CA1	Canada	2717763	4-Mar-2009	-	-	-	-	Pending
20438-0009CN1	China	200980115831.3	4-Mar-2009	CN10203755A	27-Apr-2011	-	-	Pending
20438-0009EP1	Europe	8717234	4-Mar-2008	2328290	6-Jun-2011	-	-	Pending
20438-0009JP1	Japan	2010-548683	4-Mar-2009	2011-518318	23-Jun-2011	-	-	Pending
20438-0009US1	US	12/921,349	4-Mar-2009	2011-0245092	5-Oct-2011	-	-	Pending
Combinations of Selected Biomarkers for Diagnosing Depressive Disorders								
20438-0010P01	US	81/033,721	4-Mar-2008	-	-	-	-	Expired (converted to PCT (0008WO1))
Monitoring Depressive Disorders Based on Hypothalamic-Pituitary-Adrenal (HPA) Axis Biomarkers								
20438-0011P01	US	81/033,731	4-Mar-2008	-	-	-	-	Expired (converted to PCT (0008WO1))
Inflammatory Biomarkers for Monitoring Depressive Disorders								
20438-0012P01	US	81/035,013	12-Mar-2008	-	-	-	-	Expired (converted to PCT)
20438-0012WO1	WIPO	PCT/US2008/036833	11-Mar-2009	WO 2009/114827	17-Sep-2009	-	-	Expired (national phase)
20438-0012CA1	Canada	2718273	11-Mar-2009	-	-	-	-	Pending
20438-0012CN1	China	200980116135.1	11-Mar-2009	CN 102018907A	13-Apr-2011	-	-	Pending
20438-0012EP1	Europe	9718958.3	11-Mar-2008	2272044	12-Jan-2011	-	-	Pending
20438-0012HK1	Hong Kong	11107199.1	12-Jul-2011	1153282	23-Mar-2012	-	-	Pending
20438-0012JP1	Japan	2010-550839	11-Mar-2009	2011-520095	14-Jul-2011	-	-	Pending
20438-0012US1	US	12/922,369	11-Mar-2009	2011-0298833	3-Nov-2011	-	-	Pending
Human Biomarker Hypomapping for Depressive Disorders								
20438-0013P01	US	81/105,641	15-Oct-2008	-	-	-	-	Expired (converted to PCT and utility)
20438-0013001	US	12/579,733	15-Oct-2008	2010-0100333	22-Apr-2010	-	-	Pending
20438-0013WO1	WIPO	PCT/US2008/060895	15-Oct-2008	WO 2009/030478	15-Mar-2009	-	-	Expired (national phase)
20438-0013CA1	Canada	2740738	15-Oct-2009	-	-	-	-	Pending
20438-0013CN1	China	200980147037.4	15-Oct-2008	CN 102257167A	23-Nov-2011	-	-	Pending

20436-0013EP1	Europe	9821274.9	15-Oct-2009	2337866	29-Jun-2011	-	-	Pending
20436-0013HK1	Hong Kong	12105086.4	15-Oct-2009	1164379	21-Sep-2012	-	-	Pending
20436-0013JP1	Japan	2011-0532252	15-Oct-2009	2012-508053	8-Mar-2012	-	-	Pending
Combinations of Metabolic Syndrome and HPA Axis Dysregulation for Major Depressive Disorder								
20436-0014P01	US	81/115,710	18-Nov-2008	-	-	-	-	Expired (converted to PCT and utility)
20436-0014001	US	12/820,831	18-Nov-2009	2010-0136700	3-Jun-2010	8,440,418	14-May-2013	Issued
20436-0014002	US	13/892,714	13-May-2013	-	-	-	-	Pending
20436-0014WO1	WIPO	PCT/US2009/064867	18-Nov-2008	WO 2010/059709	27-May-2010	-	-	Expired (national phase)
20436-0014CA1	Canada	2744151	18-Nov-2009	-	-	-	-	Pending
20436-0014CN1	China	200980153799.5	18-Nov-2009	CN 102301234A	28-Dec-2011	-	-	Pending
20436-0014EP1	Europe	9828159.5	18-Nov-2009	2358453	17-Aug-2011	-	-	Pending
20436-0014HK1	Hong Kong	12108344.8	18-Nov-2009	1185554	5-Oct-2012	-	-	Pending
20436-0014JP1	Japan	2011-537577	18-Nov-2009	2012-508480	19-Apr-2012	-	-	Pending
Biomarker Panels for Stratifying and Monitoring Major Depressive Disorder								
20436-0015P01	US	81/298,443	26-Jan-2010	-	-	-	-	Expired (converted to PCT and utility)
20436-0015001	US	13/014,413	26-Jan-2011	2011-0213219	1-Sep-2011	-	-	Pending
20436-0015WO1	WIPO	PCT/US2011/022573	26-Jan-2011	WO 2011/094308	4-Aug-2011	-	-	Expired (national phase)
20436-0015CA1	Canada	2758315	26-Jan-2011	-	-	-	-	Pending
20436-0015CN1	China	201150011737.8	26-Jan-2011	CN 102684428A	18-Jan-2013	-	-	Pending
20436-0015EP1	Europe	11737575.8	26-Jan-2011	2529272	5-Dec-2012	-	-	Pending
20436-0015JP1	Japan	2012-551263	26-Jan-2011	2013-518287	20-May-2013	-	-	Pending
Biomarkers for Monitoring Treatment of Neuropsychiatric Diseases								
20436-0016P01	US	81/165,862	1-Apr-2009	-	-	-	-	Expired (converted to PCT and utility)
20436-0016001	US	12/753,022	1-Apr-2010	2010-0280786	4-Nov-2010	-	-	Pending
20436-0016WO1	WIPO	PCT/US2010/029720	1-Apr-2010	WO 2010/0115061	7-Oct-2010	-	-	Expired (national phase)
20436-0016CA1	Canada	2757518	1-Apr-2010	-	-	-	-	Pending
20436-0016CN1	China	201050022306.7	1-Apr-2010	CN 102483398A	30-May-2012	-	-	Pending
20436-0016EP1	Europe	13759446.7	1-Apr-2010	2414824	8-Feb-2012	-	-	Pending
20436-0016HK1	Hong Kong	12112408.7	1-Apr-2010	1171807	5-Apr-2013	-	-	Pending
20436-0016JP1	Japan	2012-503731	1-Apr-2010	2012-522966	27-Sep-2012	-	-	Pending
Biomarkers for Monitoring Treatment of Neuropsychiatric Diseases								
20436-0017P01	US	81/188,888	8-Apr-2009	-	-	-	-	Expired (converted to PCT and utility)
20436-0017001	US	12/754,770	8-Apr-2010	2010-0280582	4-Nov-2010	-	-	Pending
20436-0017WO1	WIPO	PCT/US2010/030104	8-Apr-2010	WO 2010/118035	14-Oct-2010	-	-	Expired (national phase)
20436-0017CA1	Canada	2757899	8-Apr-2010	-	-	-	-	Pending
20436-0017CN1	China	2010800252886.8	8-Apr-2010	CN 102460153A	18-May-2012	-	-	Pending
20436-0017EP1	Europe	10752304.3	8-Apr-2010	2417448	15-Feb-2012	-	-	Pending
20436-0017HK1	Hong Kong	12111712.0	8-Apr-2010	1171081	15-Mar-2013	-	-	Pending
20436-0017JP1	Japan	2012-504782	8-Apr-2010	2012-523009	27-Sep-2012	-	-	Pending
Human Biomarker Test for Major Depressive Disorder								
20436-0018P01	US	81/788,910	15-Mar-2013	-	-	-	-	Pending
Biomarkers for Monitoring Treatment of Neuropsychiatric Diseases								
20436-0020P01	US	81/420,141	8-Dec-2010	-	-	-	-	Expired (converted to PCT and utility)
20436-0020001	US	13/312,553	8-Dec-2011	2012-0178118	7/12/2012	-	-	Pending
20436-0020WO1	WIPO	PCT/US2011/083522	8-Dec-2011	-	-	-	-	Expired (national phase)
20436-0020CA1	Canada	2820618	8-Dec-2011	-	-	-	-	Pending
20436-0020CN1	China	201160068505.2	8-Dec-2011	-	-	-	-	Pending
20436-0020EP1	Europe	11848838.2	8-Dec-2011	-	-	-	-	Pending
20436-0020JP1	Japan	unknown	8-Dec-2011	-	-	-	-	Pending
Trademarks								
Serial Number	Reg. Number	Word Mark	Check Status	Live/Dead	Registration Date			
85284705	4117318	RIDGE DIAGNOSTICS	TSOR	LIVE	3/27/2012			
85264859	4117317	RIDGE DIAGNOSTICS	TSOR	LIVE	3/27/2012			

Amended and
Restated
Secured Party
Bill of Sale
para. 4 of Kirby
Affidavit

AMENDED AND RESTATED SECURED PARTY BILL OF SALE


April 5, 2016

As a disposition of collateral at public sale pursuant to the section 9610 of the California Commercial Code, the undersigned Seller / Secured Party does hereby grant, sell, assign, transfer and convey unto itself as Buyer, and to its successors and assigns, in consideration of a partial credit bid of the secured indebtedness in the amount of Three Million and 00/100 Dollars, (\$3,000,000.00) all right, title and interest of Ridge Diagnostics, Inc., a Delaware Corporation (the "Debtor") in the Collateral described in Exhibit A to this Bill of Sale, subject to all of the terms and conditions stated herein.

This Secured Party Bill of Sale has been amended and restated to substitute a replacement Exhibit A, which more specifically describes a portion of the Collateral coming within the general description contained in the original Secured Party Bill of Sale of even date herewith.

IN WITNESS WHEREOF Secured Party has executed this Bill of Sale as of the date first above written.

VINDRAUGA HOLDINGS, LLC
A California limited liability company
By: DACA GP, LLC
A California limited liability company
Its Managing Member

By: 
James Wade, Member

///
///
///
///
///
///
///
///

This Financing Statement encumbers Debtor's current and future, right, title and interest in and to:

(a) Trademark Collateral. (i) All common law, state, federal and internationally registered trademarks, service marks, trade names, corporate names, company names, business names, fictitious business names, product names, slogans, trade styles, trade dress, color marks and designs, logos, domain names, other source or business identifiers, designs and general intangibles of like nature, now existing or hereafter adopted or acquired in any way relating to the business of Debtor ("Business") or otherwise, together with and including all licenses therefor held by Debtor, and all registrations and recordings thereof, and all applications filed or to be filed in connection therewith, and all extensions and renewals thereof, including, without limitation any of the foregoing identified on Schedule "A" hereto (as the same may be amended, modified or supplemented from time to time), together with the goodwill of the Business symbolized by or associated with all of the foregoing (collectively, the "Trademarks"); (ii) all modifications, variations, derivative marks and names based upon the Trademarks used in Debtor's Business now or in the future, and the goodwill of the Business associated with such names and marks or other Trademarks; (iii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the Trademarks, including license fees and royalties under license and other agreements; (iv) all claims, causes of action, damages and recoveries for past, present and future infringements or unauthorized use of any of the Trademarks and all rights arising therefrom and pertaining thereto; (v) all rights corresponding to the Trademarks throughout the world; (vi) all general intangibles (as defined in the UCC) and all intangible intellectual property or other similar property of Debtor of any kind or nature, whether now owned or hereafter acquired or used, associated with or arising out of any of the Trademarks (including without limitation all license, distributorship and/or franchise agreements and rights under any "Existing Interests" as defined in that certain Intellectual Property Security Agreement dated November 7, 2013 between Debtor and Secured Party) not otherwise described herein and all of the goodwill of Debtor's Business symbolized by the Trademarks or associated therewith; (vii) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (viii) all Proceeds (as defined in the Intellectual Property Security Agreement) and products of any and all of the foregoing (all of the foregoing, collectively, the "Trademark Collateral").

(b) Trade Secret Collateral. (i) All trade secrets, confidential information, know-how and other intellectual property used in the Business of Debtor now or in the future and all renewals, modifications, derivatives and improvements relating thereto (collectively, the "Trade Secrets"); (ii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the Trade Secrets, including license fees and royalties under license and other agreements; (iii) all claims, causes of action, damages and recoveries for past, present and future infringements or unauthorized use of any of the Trade Secrets and all rights arising therefrom and pertaining thereto; (iv) all rights corresponding to the Trade Secrets throughout the world; (v) all general intangibles (as defined in the UCC) and all intangible intellectual property or other

///
///
///
///

similar property of Debtor of any kind or nature, whether now owned or hereafter acquired or developed, associated with or arising out of the Trade Secrets (including without limitation all license, distributorship and/or franchise agreements and rights under any Existing Interests) and not otherwise described herein; (vi) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (vii) all Proceeds and products of any and all of the foregoing (all of the foregoing, collectively, the "Trade Secret Collateral").

(c) Copyright Collateral. (i) All published and unpublished works of authorship that Debtor owns or uses in its Business or will in the future adopt and so use (including all advertising and promotional materials, franchise agreements and franchise operation manuals) all original and derivative works of authorship and works protectable by copyright that are presently or in the future may be, owned, created, authored, acquired or used (pursuant to a license or otherwise) by Debtor or by its employees, independent contractors, third parties or acquired by Debtor, all of Debtor's proprietary object code, source code, source data files and documentation in any way related to the Business and any modifications and derivative works related thereto, all copyright registrations and applications for copyright registration that previously have been or may hereafter be issued thereon or applied for in the U.S. or anywhere in the world, all registrations resulting from such copyright applications, and all renewals, modifications, extensions, derivative works and collective works thereof or related to any of the foregoing, throughout the world, together with all copyright licenses held by Debtor, and all common law rights, copyrights, rights of authorship and moral rights related to any of the foregoing, including without limitation, any of the foregoing identified on Schedule "A" hereto (as the same may be amended, modified or supplemented from time to time) (collectively, the "Copyrights"); (ii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the foregoing, including license fees and royalties under license and other agreements; (iii) all claims, causes of action, damages and recoveries for past, present and future infringements or unauthorized use of any of the Copyrights and all rights arising therefrom and pertaining thereto; (iv) all rights corresponding to the Copyrights throughout the world; (v) all general intangibles (as defined in the UCC) and all intangible intellectual property or other similar property of Debtor of any kind or nature, whether now owned or hereafter acquired or developed, associated with or arising out of any of the Copyrights (including without limitation all license, distributorship and/or franchise agreements and rights under any Existing Interests) and not otherwise described herein; (vi) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (vii) all Proceeds and products of any and all of the foregoing (all of the foregoing, collectively, the "Copyright Collateral").

(d) Patent Collateral. (i) All patents and patent applications (including, without limitation, the inventions, devices, specifications and improvements described and claims therein) filed in the U.S. or in any other country, owned, held or used by Debtor in whole or in part, and all patent and invention disclosures related thereto, together with all reissuances, divisions, continuations, continuations-in-part, renewals, extensions, re-examinations, supplementary protection certificates, modifications, derivatives and improvements thereof and the inventions disclosed therein, and all new or separate patents that may be issued in connection with the foregoing, and all other inventions (whether patentable or unpatentable, whether or not reduced

///
///
///
///

to practice or developed alone or jointly with others), and together with and including all patent licenses held by Debtor, and all other rights, including the right to make, use, license, sell, exploit and otherwise transfer the inventions disclosed therein, including without limitation, any of the foregoing identified on Schedule "A" hereto (as the same may be amended, modified or supplemented from time to time) (collectively the "Patents"); (ii) all income, royalties and payments now or hereafter due and/or payable under and with respect to the Patents, including license fees and royalties under license and other agreements; (iii) all claims, causes of action, damages and recoveries for past, present and future infringements thereof or unauthorized use of any of the Patents and all rights arising therefrom and pertaining thereto; (iv) all rights corresponding to the Patents throughout the world; (v) all general intangibles (as defined in the UCC) and all intangible intellectual property or other similar property of Debtor of any kind or nature, whether now owned or hereafter acquired or developed, associated with or arising out of any of the Patents (including without limitation all license, distributorship and/or franchise agreements and rights under any Existing Interests) and not otherwise described herein; (vi) any jointly held rights in any of the foregoing, whether by contract or otherwise; and (vii) all products and Proceeds of any and all of the foregoing (all of the foregoing, collectively, the "Patent Collateral").

///
///
///
///
///
///
///
///
///
///

///

///

///

///

Without limiting the generality of the foregoing, this Financing Statement encumbers Debtor's current and future, right, title and interest in and to the following trademarks and patents to the fullest extent permitted under applicable law:

[See Attached Page(s)]

Ridge Diagnostics								
Schedule A to IP Security Agmt								
As at 25 May 2015								
F&R Ref.	Country	Serial No.	Filing Date	Pub. No.	Pub. Date	Patent No.	Issue Date	Status
Molecule Interaction Measurement Chip and System								
20436-0004P01	US	60/748,824	9-Dec-2005	-	-	-	-	Expired (converted to PCT)
20436-0004US1	US	12/605,950	19-Dec-2008	2010-0144052	10-Dec-2010	8,673,650	16-Mar-2014	Issued
20436-0004WO1	WIPO	PCT/US2006/047244	11-Dec-2006	WO 2007/067819	14-Jun-2007	-	-	Expired (national phase)
Molecular Interaction Detection Chip and Fabrication Process								
20436-0005P01	US	60/784,322	21-Mar-2006	-	-	-	-	Expired (converted to PCT (0004WO1))
Precision Molecule Interaction Measurement System and Method								
20436-0006P01	US	60/796,585	1-May-2006	-	-	-	-	Expired (converted to PCT (0004WO1))
Quantitative Diagnostic Methods Using Multiple Parameters								
20436-0007P01	US	11/650,550	5-Sep-2007	-	-	8,158,374	17-Apr-2012	Issued
20436-0007CA1	US	13/446,382	13-Apr-2012	2012-0288422	15-Nov-2012	8,450,677	28-May-2013	Issued
20436-0007P03	US	13/903,346	23-May-2013	2014-0135224	15-May-2014	-	-	Pending
20436-0007P01	US	60/824,471	5-Sep-2006	-	-	-	-	Expired (converted to utility)
Diagnostics with multiple parameters -algorithm and methods								
20436-0008P01	US	60/910,217	5-Apr-2007	-	-	-	-	Expired (converted to utility (0007001))
Diagnostics with multiple parameters -algorithm and methods								
20436-0009P01	US	61/033,726	4-Mar-2008	-	-	-	-	Expired (converted to PCT)
20436-0009WO1	WIPO	PCT/US2009/036084	4-Mar-2009	WO 2009/111595	11-Sep-2009	-	-	Expired (national phase)
20436-0009CA1	Canada	2717763	4-Mar-2009	-	-	-	-	Pending
20436-0009CN1	China	200960115831.0	4-Mar-2009	CN10203755A	27-Apr-2011	-	-	Pending
20436-0009EP1	Europe	9717234	4-Mar-2009	2009260	8-Jun-2011	-	-	Pending
20436-0009JP1	Japan	2010-548863	4-Mar-2009	2011-518318	29-Jun-2011	5,683,614	12-Dec-2014	Issued
20436-0009US1	US	12/921,349	4-Mar-2009	2011-0245092	6-Oct-2011	-	-	Abandoned
Combinations of Selected Biomarkers for Diagnosing Depression Disorders								
20436-0010P01	US	61/033,721	4-Mar-2008	-	-	-	-	Expired (converted to PCT (0009WO1))
Monitoring Depression Disorders Based on Hypothalamic-Pituitary-Adrenal (HPA) Axis Biomarkers								
20436-0011P01	US	61/033,731	4-Mar-2008	-	-	-	-	Expired (converted to PCT (0009WO1))
Inflammatory Biomarkers for Monitoring Depressive Disorders								
20436-0012P01	US	61/036,013	12-Mar-2008	-	-	-	-	Expired (converted to PCT)
20436-0012WO1	WIPO	PCT/US2009/036833	11-Mar-2009	WO 2009/114627	17-Sep-2009	-	-	Expired (national phase)
20436-0012CA1	Canada	2718273	11-Mar-2009	-	-	-	-	Pending
20436-0012CN1	China	200960116195.1	11-Mar-2009	CN102016907A	13-Apr-2011	-	-	Pending
20436-0012EP1	Europe	9718968.3	11-Mar-2009	2272044	12-Jan-2011	-	-	Pending
20436-0012HK1	Hong Kong	11107193.1	12-Jul-2011	1183282	23-Mar-2012	-	-	Pending
20436-0012JP1	Japan	2010-550839	11-Mar-2009	2011-520095	14-Jul-2011	5,658,571	5-Dec-2014	Issued
20436-0012US1	US	12/922,365	11-Mar-2009	2011-0269633	3-Nov-2011	-	-	Abandoned
Human Biomarker Hypermapping for Depressive Disorders								
20436-0013P01	US	61/105,641	15-Oct-2008	-	-	-	-	Expired (converted to PCT and utility)
20436-0013001	US	12/579,733	12-Oct-2009	2010-0100333	22-Apr-2010	-	-	Abandoned
20436-0013WO1	WIPO	PCT/US2009/060895	15-Oct-2009	WO 2007/030475	15-Mar-2007	-	-	Expired (national phase)
20436-0013CA1	Canada	2740706	15-Oct-2009	-	-	-	-	Pending
20436-0013CN1	China	200960147037.4	15-Oct-2009	CN 102257157A	23-Nov-2011	-	-	Abandoned
20436-0013EP1	Europe	9801274.9	15-Oct-2009	2007995	29-Jun-2011	2,337,866	30-Jul-2014	Issued (Germany, France, Great Britain)
20436-0013HK1	Hong Kong	12105066.4	15-Oct-2009	1164379	21-Sep-2012	-	-	Abandoned
20436-0013JP1	Japan	2011-0502062	15-Oct-2009	2012-506053	8-Mar-2012	5,540,000	9-May-2014	Issued
Combinations of Metabolic Syndrome and HPA Axis Biomarkers for Monitoring Major Depressive Disorder								
20436-0014P01	US	61/115,710	18-Nov-2008	-	-	-	-	Expired (converted to PCT and utility)
20436-0014001	US	12/620,831	18-Nov-2009	2010-0136700	3-Jun-2010	8,440,418	14-May-2013	Issued
20436-0014002	US	13/892,714	13-May-2013	-	-	-	-	Abandoned
20436-0014WO1	WIPO	PCT/US2009/064967	18-Nov-2009	WO 2010/059709	27-May-2010	-	-	Expired (national phase)
20436-0014CA1	Canada	2744151	18-Nov-2009	-	-	-	-	Pending
20436-0014CN1	China	200960153799.5	18-Nov-2009	CN 102301234A	23-Dec-2011	-	-	Allowed
20436-0014EP1	Europe	9808159.5	18-Nov-2009	2056453	17-Aug-2011	-	-	Pending
20436-0014HK1	Hong Kong	12106044.6	18-Nov-2009	1185554	5-Oct-2012	-	-	Pending
20436-0014JP1	Japan	2011-537577	18-Nov-2009	2012-509480	19-Apr-2012	-	-	Pending
Biomarker Panels for Stratifying and Monitoring Major Depressive Disorder								
20436-0015P01	US	61/298,443	26-Jan-2010	-	-	-	-	Expired (converted to PCT and utility)
20436-0015001	US	13/014,413	26-Jan-2011	2011-0213219	1-Sep-2011	-	-	To be abandoned
20436-0015WO1	WIPO	PCT/US2011/022573	26-Jan-2011	WO 2011/094308	4-Aug-2011	-	-	Expired (national phase)
20436-0015CA1	Canada	2768315	26-Jan-2011	-	-	-	-	Pending

Ridge Diagnostics		**CONFIDENTIAL**						
Schedule A to IP Security Agmt								
As at 25 May 2015								
F&R Ref.	Country	Serial No.	Filing Date	Pub. No.	Pub. Date	Patent No.	Issue Date	Status
20436-001SON1	China	201180011737.8	26-Jan-2011	CN 102884428A	16-Jan-2013	-	-	Pending
20436-001SEP1	Europe	11737575.8	26-Jan-2011	2529222	8-Dec-2012	-	-	Pending
20436-001SJP1	Japan	2012-551263	26-Jan-2011	2013-518267	20-May-2013	-	-	Pending
Biomarkers for Monitoring Treatment of Neuropsychiatric Diseases								
20436-0016P01	US	61/165,662	1-Apr-2009	-	-	-	-	Expired (converted to PCT and utility)
20436-0016001	US	12/753,022	1-Apr-2010	2010-0280760	4-Nov-2010	-	-	Abandoned
20436-0016WO1	WIPO	PCT/US2010/029720	1-Apr-2010	WO 2010/0115061	7-Oct-2010	-	-	Expired (national phase)
20436-0016CA1	Canada	2757518	1-Apr-2010	-	-	-	-	Pending
20436-0016CN1	China	201060022306.7	1-Apr-2010	CN 102483388A	30-May-2012	-	-	Pending
20436-0016EP1	Europe	10759448.7	1-Apr-2010	2414824	8-Feb-2012	-	-	Pending
20436-0016HK1	Hong Kong	12112468.7	1-Apr-2010	1171867	5-Apr-2013	-	-	Pending
20436-0016JP1	Japan	2012-503731	1-Apr-2010	2012-522995	27-Sep-2012	5,875,771	9-Jan-2015	Issued
Biomarkers for Monitoring Treatment of Neuropsychiatric Diseases								
20436-0017P01	US	61/166,986	6-Apr-2009	-	-	-	-	Expired (converted to PCT and utility)
20436-0017001	US	12/754,770	6-Apr-2010	2010-0280562	4-Nov-2010	-	-	Abandoned
20436-0017WO1	WIPO	PCT/US2010/030104	6-Apr-2010	WO 2010/118035	14-Oct-2010	-	-	Expired (national phase)
20436-0017CA1	Canada	2757559	6-Apr-2010	-	-	-	-	Pending
20436-0017CN1	China	2010800253266.8	6-Apr-2010	CN 102480153A	16-May-2012	-	-	Pending
20436-0017EP1	Europe	10762304.3	6-Apr-2010	2417448	18-Feb-2012	-	-	Pending
20436-0017NK	Hong Kong	12111712.0	6-Apr-2010	1171661	15-Mar-2013	-	-	Pending
20436-0017JP1	Japan	2012-504782	6-Apr-2010	2012-523009	27-Sep-2012	-	-	Abandoned
Human Biomarker Test for Major Depressive Disorder								
20436-0018P01	US	61/798,910	15-Mar-2013	-	-	-	-	Expired
20436-0018001	US	14/211,560	14-Mar-2014	-	-	-	-	Pending
20436-0018WO1	WIPO	PCT/US2014/027774	14-Mar-2014	-	-	-	-	Pending
Biomarkers for Monitoring Treatment of Neuropsychiatric Diseases								
20436-0020P01	US	61/420,141	6-Dec-2010	-	-	-	-	Expired (converted to PCT and utility)
20436-0020001	US	13/312,553	6-Dec-2011	2012-0178118	7/12/2012	-	-	Abandoned
20436-0020WO1	WIPO	PCT/US2011/063522	6-Dec-2011	-	-	-	-	Expired (national phase)
20436-0020CA1	Canada	2800618	6-Dec-2011	-	-	-	-	Pending
20436-0020CN1	China	201180066505.2	6-Dec-2011	-	-	-	-	Pending
20436-0020EP1	Europe	11346636.2	6-Dec-2011	-	-	-	-	Pending
20436-0020JP1	Japan	unknown	6-Dec-2011	-	-	-	-	Pending
Diagnosing and Monitoring Disease States								
20436-0031001	US	14/154,969	14-Jan-2014	-	-	-	-	Pending
Biomarkers and algorithms for identifying comorbid depression and chronic pain								
20436-0032P01	US	62/060,933	2-Jun-2014	-	-	-	-	Pending
Multiple Biomarker Panels to Stratify Disease Severity and Monitor Treatment of Depression								
20436-0033001	US	14/289,303	9-Jun-2014	-	-	-	-	Pending